|
G |
Acbd3 |
acyl-Coenzyme A binding domain containing 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:180,553,608...180,581,769
Ensembl chr 1:180,553,608...180,581,769
|
|
G |
Aco2 |
aconitase 2, mitochondrial |
multiple interactions |
ISO |
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical |
CTD |
PMID:16162655 |
|
NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
|
|
G |
Ankar |
ankyrin and armadillo repeat containing |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in increased expression of ANKAR mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:72,682,139...72,739,743
Ensembl chr 1:72,682,139...72,739,738
|
|
G |
Arap1 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ARAP1-AS1 mRNA] which results in increased expression of ARAP1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:100,997,268...101,061,793
Ensembl chr 7:100,997,274...101,061,793
|
|
G |
BC034090 |
cDNA sequence BC034090 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of KIAA1614-AS1 mRNA] which results in increased expression of KIAA1614 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:155,088,217...155,123,504
Ensembl chr 1:155,088,217...155,120,190
|
|
G |
Cat |
catalase |
decreases response to substance multiple interactions |
ISO |
CAT protein results in decreased susceptibility to Hydroxyl Radical CAT protein inhibits the reaction [chromium hexavalent ion results in increased chemical synthesis of Hydroxyl Radical] |
CTD |
PMID:10421593 PMID:11678602 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Catip |
ciliogenesis associated TTC17 interacting protein |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CATIP-AS1 mRNA] which results in increased expression of CATIP mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:74,401,272...74,408,482
Ensembl chr 1:74,401,267...74,408,480
|
|
G |
Cblif |
cobalamin binding intrinsic factor |
affects metabolic processing |
ISO |
CBLIF protein affects the metabolism of Hydroxyl Radical |
CTD |
PMID:11750760 |
|
NCBI chr19:11,724,907...11,740,811
Ensembl chr19:11,724,918...11,740,811
|
|
G |
Ccdc183 |
coiled-coil domain containing 183 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CCDC183-AS1 mRNA] which results in increased expression of CCDC183 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 2:25,498,641...25,507,690
Ensembl chr 2:25,498,647...25,507,690
|
|
G |
Col4a2 |
collagen, type IV, alpha 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of COL4A2-AS1 mRNA] which results in decreased expression of COL4A2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:11,362,805...11,499,287
Ensembl chr 8:11,362,805...11,499,287
|
|
G |
Coro1a |
coronin, actin binding protein 1A |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of CORO1A-AS1 mRNA] which results in decreased expression of CORO1A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:126,298,946...126,303,988
Ensembl chr 7:126,298,945...126,306,959
|
|
G |
Dcxr |
dicarbonyl L-xylulose reductase |
multiple interactions increases chemical synthesis |
ISO |
[DCXR protein results in increased metabolism of 9,10-phenanthrenequinone] which results in increased chemical synthesis of Hydroxyl Radical DCXR protein results in increased chemical synthesis of Hydroxyl Radical |
CTD |
PMID:28595002 |
|
NCBI chr11:120,615,372...120,618,110
Ensembl chr11:120,616,225...120,618,107
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of DDIT4-AS1 mRNA] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Ddx59 |
DEAD box helicase 59 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DDX59-AS1 mRNA] which results in increased expression of DDX59 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:136,343,009...136,384,019
Ensembl chr 1:136,343,009...136,367,896
|
|
G |
Dlgap1 |
DLG associated protein 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DLGAP1-AS2 mRNA] which results in increased expression of DLGAP1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr17:70,276,068...71,128,408
Ensembl chr17:70,276,068...71,128,408
|
|
G |
Dnmt3l |
DNA (cytosine-5-)-methyltransferase 3-like |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of DNMT3L mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:77,878,121...77,899,456
Ensembl chr10:77,877,781...77,899,456
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC02019 mRNA] which results in increased expression of DOCK3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:106,770,024...107,109,108
Ensembl chr 9:106,770,024...107,109,108
|
|
G |
Dynlt2b |
dynein light chain Tctex-type 2B |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in increased expression of DYNLT2B mRNA |
CTD |
PMID:33656867 |
|
NCBI chr16:32,238,520...32,247,917
Ensembl chr16:32,238,520...32,247,917
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CSRP3-AS1 mRNA] which results in increased expression of E2F8 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344
|
|
G |
Fam83f |
family with sequence similarity 83, member F |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNRC6B-DT mRNA] which results in increased expression of FAM83F mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:80,556,048...80,584,626
Ensembl chr15:80,556,048...80,584,626
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fhad1 |
forkhead-associated (FHA) phosphopeptide binding domain 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FHAD1-AS1 mRNA] which results in increased expression of FHAD1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:141,617,741...141,742,438
Ensembl chr 4:141,617,749...141,742,393
|
|
G |
Flnb |
filamin, beta |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FLNB-AS1 mRNA] which results in decreased expression of FLNB mRNA |
CTD |
PMID:33656867 |
|
NCBI chr14:14,518,185...14,651,852
Ensembl chr14:14,518,185...14,651,816
|
|
G |
Flnc |
filamin C, gamma |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FLNC-AS1 mRNA] which results in increased expression of FLNC mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
increases abundance multiple interactions |
ISO |
FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:27385396 |
|
NCBI chr X:67,722,142...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Foxc2 |
forkhead box C2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FOXC2-AS1 mRNA] which results in decreased expression of FOXC2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:121,842,910...121,845,634
Ensembl chr 8:121,842,910...121,845,634
|
|
G |
Foxl2 |
forkhead box L2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01391 mRNA] which results in increased expression of FOXL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:98,837,660...98,840,179
Ensembl chr 9:98,837,341...98,840,596
|
|
G |
Gcc2 |
GRIP and coiled-coil domain containing 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:58,091,217...58,141,421
Ensembl chr10:58,091,319...58,141,421
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-AS1 mRNA] which results in increased expression of GK mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:84,745,543...84,820,425
Ensembl chr X:84,745,543...84,820,425
|
|
G |
Gsn |
gelsolin |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of GSN-AS1 mRNA] which results in decreased expression of GSN mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 2:35,146,371...35,197,914
Ensembl chr 2:35,146,392...35,197,904
|
|
G |
Hoxb9 |
homeobox B9 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXB-AS4 mRNA] which results in increased expression of HOXB9 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:96,162,156...96,167,421
Ensembl chr11:96,162,283...96,167,421
|
|
G |
Hoxc13 |
homeobox C13 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXC13-AS mRNA] which results in increased expression of HOXC13 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:102,829,566...102,837,249
Ensembl chr15:102,829,538...102,837,249
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
multiple interactions |
ISO |
HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]; Oxygen deficiency inhibits the reaction [HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]] |
CTD |
PMID:14971653 |
|
NCBI chr 7:140,769,847...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Iapp |
islet amyloid polypeptide |
multiple interactions |
ISO |
IAPP protein promotes the reaction [[Copper co-treated with Ascorbic Acid] results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:23793354 |
|
NCBI chr 6:142,244,151...142,249,546
Ensembl chr 6:142,244,149...142,249,687
|
|
G |
Icosl |
icos ligand |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of ICOSLG mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:77,904,921...77,915,359
Ensembl chr10:77,905,136...77,919,747
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of INSIG1-DT mRNA] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
|
|
G |
Itga3 |
integrin alpha 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PICART1 mRNA] which results in decreased expression of ITGA3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:94,935,301...94,967,637
Ensembl chr11:94,935,300...94,967,627
|
|
G |
Krt7 |
keratin 7 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of KRT7-AS mRNA] which results in decreased expression of KRT7 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:101,310,284...101,325,687
Ensembl chr15:101,308,924...101,328,194
|
|
G |
Lbx2 |
ladybird homeobox 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of LBX2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 6:83,063,346...83,065,224
Ensembl chr 6:83,063,348...83,065,224
|
|
G |
Lif |
leukemia inhibitory factor |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LIF-AS1 mRNA] which results in increased expression of LIF mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:4,207,568...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of MMEL1-AS1 mRNA] which results in decreased expression of MMEL1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:154,954,042...154,979,987
Ensembl chr 4:154,954,042...154,979,985
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
decreases degradation |
ISO |
Hydroxyl Radical results in decreased degradation of MSR1 mRNA |
CTD |
PMID:9614211 |
|
NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
ISO |
[[MT3 protein binds to Zinc] which co-treated with Ascorbic Acid] inhibits the reaction [Copper results in increased chemical synthesis of Hydroxyl Radical] |
CTD |
PMID:17389590 |
|
NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774
|
|
G |
Ngfr |
nerve growth factor receptor (TNFR superfamily, member 16) |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of NGFR-AS1 mRNA] which results in increased expression of NGFR mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:95,459,644...95,478,524
Ensembl chr11:95,459,644...95,478,561
|
|
G |
Nucb1 |
nucleobindin 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of NUCB1-AS1 mRNA] which results in decreased expression of NUCB1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:45,142,098...45,159,832
Ensembl chr 7:45,139,882...45,159,830
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein] |
CTD |
PMID:14623030 |
|
NCBI chr12:17,594,809...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Odf3l1 |
outer dense fiber of sperm tails 3-like 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNM1P35 mRNA] which results in increased expression of ODF3L1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:56,755,940...56,779,199
Ensembl chr 9:56,755,943...56,771,963
|
|
G |
Osgepl1 |
O-sialoglycoprotein endopeptidase-like 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in decreased expression of OSGEPL1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:53,352,070...53,365,502
Ensembl chr 1:53,352,783...53,365,502
|
|
G |
Piwil2 |
piwi-like RNA-mediated gene silencing 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of PIWIL2-DT mRNA] which results in increased expression of PIWIL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr14:70,609,926...70,674,338
Ensembl chr14:70,609,926...70,666,832
|
|
G |
Pla2g4e |
phospholipase A2, group IVE |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLA2G4E-AS1 mRNA] which results in increased expression of PLA2G4E mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 2:119,996,893...120,077,306
Ensembl chr 2:119,996,893...120,075,816
|
|
G |
Plcl2 |
phospholipase C-like 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLCL2-AS1 mRNA] which results in increased expression of PLCL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr17:50,815,893...50,995,522
Ensembl chr17:50,816,431...50,995,512
|
|
G |
Polh |
polymerase (DNA directed), eta (RAD 30 related) |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of POLH-AS1 mRNA] which results in increased expression of POLH mRNA |
CTD |
PMID:33656867 |
|
NCBI chr17:46,482,281...46,513,567
Ensembl chr17:46,482,281...46,513,571
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO EXP |
[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical [POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; Dimethyl Sulfoxide inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:21215309 |
|
NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180
|
|
G |
Prickle2 |
prickle planar cell polarity protein 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS1 mRNA] which results in increased expression of PRICKLE2 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS3 mRNA] which results in increased expression of PRICKLE2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 6:92,347,873...92,683,464
Ensembl chr 6:92,347,889...92,683,136
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
[[Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein] which results in decreased secretion of SERPINE1 protein |
CTD |
PMID:11681624 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sh3rf3 |
SH3 domain containing ring finger 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of SH3RF3-AS1 mRNA] which results in decreased expression of SH3RF3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:58,649,181...58,974,738
Ensembl chr10:58,649,181...58,974,738
|
|
G |
Smad5 |
SMAD family member 5 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SMAD5-AS1 mRNA] which results in increased expression of SMAD5 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr13:56,850,804...56,890,191
Ensembl chr13:56,850,823...56,890,190
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SYP-AS1 mRNA] which results in increased expression of SYP mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495
|
|
G |
Tab3 |
TGF-beta activated kinase 1/MAP3K7 binding protein 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS1 mRNA] which results in increased expression of TAB3 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS2 mRNA] which results in increased expression of TAB3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:84,617,466...84,678,075
Ensembl chr X:84,617,628...84,678,075
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of THY1-AS1 mRNA] which results in decreased expression of THY1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Tlx2 |
T cell leukemia, homeobox 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of TLX2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 6:83,045,306...83,047,206
Ensembl chr 6:83,045,305...83,047,274
|
|
G |
Tm4sf19 |
transmembrane 4 L six family member 19 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in decreased expression of TM4SF19 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr16:32,218,823...32,227,397
Ensembl chr16:32,219,324...32,227,045
|
|
G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNFRSF10A-AS1 mRNA] which results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr14:70,004,921...70,021,860
Ensembl chr14:70,004,921...70,021,860
|
|
G |
Ttc23l |
tetratricopeptide repeat domain 23-like |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TTC23L-AS1 mRNA] which results in increased expression of TTC23L mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:10,497,309...10,559,006
Ensembl chr15:10,500,188...10,558,754
|
|
G |
Upk1a |
uroplakin 1A |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of UPK1A-AS1 mRNA] which results in increased expression of UPK1A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:30,302,517...30,312,159
Ensembl chr 7:30,302,517...30,312,272
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions increases abundance |
ISO |
[[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical XDH protein results in increased abundance of Hydroxyl Radical |
CTD |
PMID:7929072 |
|
NCBI chr17:74,190,890...74,257,369
Ensembl chr17:74,190,890...74,257,191
|
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
multiple interactions |
EXP |
ABCC1 protein affects the reaction [AGT protein results in decreased abundance of Nitric Oxide]; ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Glutathione]; ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Iron] |
CTD |
PMID:16679408 PMID:17272743 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
multiple interactions |
ISO |
ABCC2 affects the reaction [Ursodeoxycholic Acid results in increased secretion of Nitric Oxide] ABCC2 gene SNP affects the susceptibility to [Air Pollutants results in increased abundance of Nitric Oxide] |
CTD |
PMID:20683964 PMID:29681089 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Acbd3 |
acyl-Coenzyme A binding domain containing 3 |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr 1:180,553,608...180,581,769
Ensembl chr 1:180,553,608...180,581,769
|
|
G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
multiple interactions increases expression |
ISO |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA] |
CTD |
PMID:10948087 PMID:16326922 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Aco1 |
aconitase 1 |
decreases expression multiple interactions |
EXP |
Nitric Oxide results in decreased expression of ACO1 mRNA STAT5A protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA]; STAT5B protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] |
CTD |
PMID:16886906 |
|
NCBI chr 4:40,143,265...40,199,009
Ensembl chr 4:40,143,081...40,198,338
|
|
G |
Acta1 |
actin alpha 1, skeletal muscle |
multiple interactions increases expression |
ISO |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA] |
CTD |
PMID:10397678 PMID:16326922 |
|
NCBI chr 8:124,618,497...124,621,514
Ensembl chr 8:124,618,508...124,621,490
|
|
G |
Actb |
actin, beta |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of ACTB mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Adm |
adrenomedullin |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of ADM mRNA |
CTD |
PMID:16326922 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Adm2 |
adrenomedullin 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of ADM2 mRNA |
CTD |
PMID:16326922 |
|
NCBI chr15:89,206,923...89,208,934
Ensembl chr15:89,206,923...89,208,934
|
|
G |
Adrb2 |
adrenergic receptor, beta 2 |
decreases abundance |
EXP |
ADRB2 protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:10580815 |
|
NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030
|
|
G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
decreases secretion increases chemical synthesis increases activity increases abundance increases secretion decreases abundance multiple interactions |
ISO EXP |
AGT protein modified form results in decreased secretion of Nitric Oxide AGT protein modified form results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in increased activity of AGT protein modified form AGT protein results in increased abundance of Nitric Oxide AGT protein alternative form results in increased secretion of Nitric Oxide AGT protein results in decreased abundance of Nitric Oxide AGT protein alternative form promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; PD 123319 inhibits the reaction [AGT protein results in increased abundance of Nitric Oxide]; Valsartan inhibits the reaction [AGT protein results in increased abundance of Nitric Oxide]; Valsartan inhibits the reaction [AGT protein results in increased secretion of Nitric Oxide] ABCC1 protein affects the reaction [AGT protein results in decreased abundance of Nitric Oxide] candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Nitric Oxide]; Hydrogen Sulfide promotes the reaction [AGT protein modified form results in increased chemical synthesis of Nitric Oxide]; Losartan inhibits the reaction [AGT protein modified form results in decreased secretion of Nitric Oxide]; troglitazone inhibits the reaction [AGT protein modified form results in decreased secretion of Nitric Oxide] |
CTD |
PMID:12198334 PMID:14597853 PMID:14620932 PMID:17272743 PMID:17666345 PMID:18551021 PMID:18990443 PMID:29084084 More...
|
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
affects abundance |
ISO |
AGTR1A protein affects the abundance of Nitric Oxide |
CTD |
PMID:19151255 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
affects abundance |
ISO |
AGTR1B protein affects the abundance of Nitric Oxide |
CTD |
PMID:19151255 |
|
NCBI chr 3:20,368,637...20,421,341
Ensembl chr 3:20,368,637...20,421,341
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
affects response to substance |
ISO |
AGTR2 protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:9374809 |
|
NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
affects localization |
ISO |
Nitric Oxide affects the localization of AIFM1 protein |
CTD |
PMID:15126337 |
|
NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of AIMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:132,366,259...132,390,151
Ensembl chr 3:132,366,242...132,390,131
|
|
G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of AIP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr19:4,163,756...4,177,233
Ensembl chr19:4,164,446...4,175,858
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Nitric Oxide] |
CTD |
PMID:18245901 |
|
NCBI chr12:112,620,255...112,641,318
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2, mitochondrial |
multiple interactions |
EXP |
[ALDH2 protein affects the metabolism of and results in increased susceptibility to Pentaerythritol Tetranitrate] which results in increased abundance of Nitric Oxide |
CTD |
PMID:21156756 |
|
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [Reactive Oxygen Species results in decreased activity of ALOX5 protein] |
CTD |
PMID:12388339 |
|
NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139
|
|
G |
Angptl2 |
angiopoietin-like 2 |
decreases chemical synthesis |
EXP |
ANGPTL2 gene mutant form results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:27402837 |
|
NCBI chr 2:33,105,963...33,137,737
Ensembl chr 2:33,106,081...33,137,729
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
Nitric Oxide results in increased expression of ANXA5 protein |
CTD |
PMID:16024610 |
|
NCBI chr 3:36,503,072...36,530,036
Ensembl chr 3:36,503,072...36,530,043
|
|
G |
Apoe |
apolipoprotein E |
decreases chemical synthesis |
EXP |
APOE gene mutant form results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:11397713 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
App |
amyloid beta (A4) precursor protein |
multiple interactions |
EXP |
[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Ibuprofen inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Indomethacin inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:11080519 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Aqp2 |
aquaporin 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of AQP2 protein |
CTD |
PMID:17940347 |
|
NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
increases response to substance |
EXP |
ASS1 protein results in increased susceptibility to Nitric Oxide |
CTD |
PMID:25033204 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [Clofibrate results in increased expression of ATP1A1 protein] |
CTD |
PMID:15018640 |
|
NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000
|
|
G |
Atp5b |
ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of ATP5B mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
|
|
G |
Avp |
arginine vasopressin |
affects metabolic processing increases expression multiple interactions |
ISO |
AVP protein affects the metabolism of Nitric Oxide Nitric Oxide results in increased expression of AVP mRNA IL1B protein affects the reaction [AVP protein affects the metabolism of Nitric Oxide] |
CTD |
PMID:10460269 PMID:21171372 |
|
NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474
|
|
G |
Axl |
AXL receptor tyrosine kinase |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of AXL mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:25,455,925...25,488,502
Ensembl chr 7:25,456,698...25,488,130
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
Nitric Oxide results in increased expression of B2M protein |
CTD |
PMID:15764486 |
|
NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564
|
|
G |
Bax |
BCL2-associated X protein |
affects localization multiple interactions decreases expression |
EXP ISO |
Nitric Oxide affects the localization of BAX protein Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in increased expression of and affects the localization of BAX protein] [Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein] Nitric Oxide results in decreased expression of BAX protein [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of BAX protein |
CTD |
PMID:10828028 PMID:14634119 PMID:22878015 PMID:25726415 |
|
NCBI chr 7:45,111,119...45,116,344
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
increases expression |
ISO |
Nitric Oxide results in increased expression of BBC3 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr 7:16,042,307...16,052,259
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcar1 |
breast cancer anti-estrogen resistance 1 |
multiple interactions decreases phosphorylation |
ISO |
Nitric Oxide inhibits the reaction [BCAR1 protein binds to CRK protein] Nitric Oxide results in decreased phosphorylation of BCAR1 protein |
CTD |
PMID:12714323 |
|
NCBI chr 8:112,437,106...112,470,481
Ensembl chr 8:112,437,106...112,470,441
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression affects expression multiple interactions |
ISO EXP |
Nitric Oxide results in decreased expression of BCL2 protein Nitric Oxide affects the expression of BCL2 mRNA [3,5-dimethoxy-4'-hydroxystilbene results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 mRNA; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 protein; [Quercetin results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased expression of BCL2 protein; Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein; pimagedine inhibits the reaction [Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein] |
CTD |
PMID:7706495 PMID:10828028 PMID:15126337 PMID:16980304 PMID:17135264 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression increases expression multiple interactions |
ISO |
Nitric Oxide results in decreased expression of BCL2L1 protein Nitric Oxide results in increased expression of BCL2L1 mRNA GATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]; GATA5 protein promotes the reaction [Nitric Oxide results in increased expression of BCL2L1 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]; Nitric Oxide results in increased expression of and affects the localization of BCL2L1 protein |
CTD |
PMID:15126337 PMID:25726415 |
|
NCBI chr 2:152,600,652...152,675,723
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdkrb2 |
bradykinin receptor, beta 2 |
multiple interactions |
ISO |
[kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:29775649 |
|
NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases chemical synthesis multiple interactions |
ISO |
BDNF protein results in increased chemical synthesis of Nitric Oxide 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:17172126 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage |
ISO |
Nitric Oxide results in increased cleavage of BID protein |
CTD |
PMID:15126337 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
EXP |
Nitric Oxide results in increased expression of BIRC2 protein |
CTD |
PMID:14634119 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression decreases expression |
EXP ISO |
Nitric Oxide results in increased expression of BIRC3 protein Nitric Oxide results in decreased expression of BIRC3 mRNA |
CTD |
PMID:14634119 PMID:15126337 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO EXP |
Nitric Oxide results in decreased expression of BIRC5 mRNA Nitric Oxide results in decreased expression of BIRC5 protein |
CTD |
PMID:15126337 PMID:16166326 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of BMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr14:70,711,995...70,758,280
Ensembl chr14:70,711,998...70,757,674
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression decreases expression |
ISO EXP |
Nitric Oxide results in increased expression of BNIP3 protein Nitric Oxide results in decreased expression of BNIP3 mRNA |
CTD |
PMID:11592958 PMID:16002567 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Cacna1a |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
multiple interactions |
ISO |
CACNA1A protein affects the reaction [Potassium Chloride results in increased abundance of Nitric Oxide] |
CTD |
PMID:12770949 |
|
NCBI chr 8:85,065,257...85,366,880
Ensembl chr 8:85,065,268...85,366,875
|
|
G |
Cacna1b |
calcium channel, voltage-dependent, N type, alpha 1B subunit |
multiple interactions |
ISO |
CACNA1B protein affects the reaction [Potassium Chloride results in increased abundance of Nitric Oxide] |
CTD |
PMID:12770949 |
|
NCBI chr 2:24,493,872...24,653,210
Ensembl chr 2:24,493,899...24,653,164
|
|
G |
Calcrl |
calcitonin receptor-like |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of CALCRL mRNA; Nitric Oxide deficiency results in increased expression of CALCRL protein |
CTD |
PMID:16326922 |
|
NCBI chr 2:84,160,970...84,255,786
Ensembl chr 2:84,160,970...84,255,755
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:17098364 |
|
NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased activity of and results in increased cleavage of CASP1 protein |
CTD |
PMID:10903723 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases metabolic processing decreases activity decreases cleavage |
ISO EXP |
[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of CASP3 protein]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein]; Dithiothreitol inhibits the reaction [Nitric Oxide results in decreased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein] Nitric Oxide results in increased activity of CASP3 protein Nitric Oxide results in increased metabolism of CASP3 protein [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one inhibits the reaction [[Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]]; Nitric Oxide affects the activity of and affects the cleavage of CASP3 protein; Nitric Oxide results in decreased cleavage of and results in decreased activity of CASP3 protein [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein] Nitric Oxide results in decreased cleavage of CASP3 protein |
CTD |
PMID:9388267 PMID:9706149 PMID:9755104 PMID:10222263 PMID:10358093 PMID:10728388 PMID:10811113 PMID:10828028 PMID:12606818 PMID:14634119 PMID:15126337 PMID:20020783 PMID:20179380 PMID:22878015 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
decreases cleavage |
ISO |
Nitric Oxide results in decreased cleavage of CASP7 protein |
CTD |
PMID:10222263 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO EXP |
Nitric Oxide results in decreased cleavage of and results in decreased activity of CASP8 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP8 protein Nitric Oxide results in increased activity of CASP8 protein |
CTD |
PMID:10358093 PMID:15126337 PMID:22878015 |
|
NCBI chr 1:58,834,398...58,886,662
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
decreases activity multiple interactions increases activity |
EXP ISO |
Nitric Oxide results in decreased activity of CASP9 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP9 protein Nitric Oxide results in increased activity of CASP9 protein |
CTD |
PMID:14634119 PMID:15126337 PMID:22878015 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of CAT mRNA]; Nitric Oxide promotes the reaction [Sertraline inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]]; Nitric Oxide promotes the reaction [Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]] |
CTD |
PMID:20305041 PMID:21983654 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cav1 |
caveolin 1, caveolae protein |
multiple interactions increases expression |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide; Nitric Oxide results in decreased ubiquitination of and results in decreased degradation of CAV1 protein; Nitric Oxide results in increased metabolism of and results in increased stability of CAV1 protein Nitric Oxide results in increased expression of CAV1 protein |
CTD |
PMID:18296501 PMID:19706615 |
|
NCBI chr 6:17,306,287...17,341,327
Ensembl chr 6:17,306,334...17,341,451
|
|
G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
decreases secretion multiple interactions |
ISO EXP |
Nitric Oxide results in decreased secretion of CCL5 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; [CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide; Disulfiram inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:13678430 PMID:19016906 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
[[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein |
CTD |
PMID:24412304 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccr5 |
chemokine (C-C motif) receptor 5 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; [CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide; Disulfiram inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:19016906 |
|
NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736
|
|
G |
Cd14 |
CD14 antigen |
multiple interactions |
ISO |
CD14 protein affects the reaction [G(M1) Ganglioside results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [ganglioside, GD1a results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [Gangliosides results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [trisialoganglioside GT1 results in increased secretion of Nitric Oxide] |
CTD |
PMID:16651628 |
|
NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851
|
|
G |
Cd28 |
CD28 antigen |
multiple interactions increases abundance |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 5-diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:14607919 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Cd86 |
CD86 antigen |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of CD86 protein |
CTD |
PMID:13678430 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of CDH1 mRNA |
CTD |
PMID:20179380 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdx2 |
caudal type homeobox 2 |
increases chemical synthesis |
EXP |
CDX2 gene mutant form results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:29439001 |
|
NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions |
ISO |
Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]] |
CTD |
PMID:12612912 |
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1, CNS |
multiple interactions |
ISO |
[(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to CHRM1 protein] which results in increased abundance of Nitric Oxide; [muscarinic toxin 7 binds to and results in decreased activity of CHRM1 protein] inhibits the reaction [Amphetamine results in increased abundance of Nitric Oxide] |
CTD |
PMID:18991861 |
|
NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951
|
|
G |
Cnr1 |
cannabinoid receptor 1 (brain) |
multiple interactions |
EXP ISO |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; CNR1 protein affects the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in decreased abundance of Nitric Oxide]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in decreased abundance of Nitric Oxide] |
CTD |
PMID:10027878 PMID:11727767 PMID:11891798 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Col1a2 |
collagen, type I, alpha 2 |
multiple interactions increases expression |
ISO |
Amlodipine inhibits the reaction [Nitric Oxide deficiency results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10445667 |
|
NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
|
|
G |
Col5a3 |
collagen, type V, alpha 3 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of COL5A3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:20,681,353...20,726,363
Ensembl chr 9:20,681,346...20,726,363
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4I1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of COX4I1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946
|
|
G |
Cpd |
carboxypeptidase D |
affects chemical synthesis multiple interactions |
ISO |
CPD affects the chemical synthesis of Nitric Oxide [PRL results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide; [Testosterone results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:21688280 |
|
NCBI chr11:76,668,034...76,737,834
Ensembl chr11:76,669,250...76,737,844
|
|
G |
Cps1 |
carbamoyl-phosphate synthetase 1 |
affects abundance |
ISO |
CPS1 gene SNP affects the abundance of Nitric Oxide metabolite |
CTD |
PMID:14718356 |
|
NCBI chr 1:67,151,294...67,270,426
Ensembl chr 1:67,162,185...67,270,418
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases expression |
ISO |
CRH protein affects the reaction [Nitric Oxide results in increased secretion of POMC protein alternative form] Nitric Oxide results in increased expression of CRH mRNA |
CTD |
PMID:10460269 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of CRHR1 mRNA |
CTD |
PMID:10460269 |
|
NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349
|
|
G |
Crk |
v-crk avian sarcoma virus CT10 oncogene homolog |
multiple interactions |
ISO |
Nitric Oxide inhibits the reaction [BCAR1 protein binds to CRK protein] |
CTD |
PMID:12714323 |
|
NCBI chr11:75,570,020...75,599,254
Ensembl chr11:75,570,085...75,597,734
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions decreases activity |
ISO EXP |
[CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; [Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; CSF1 protein promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; Enzyme Inhibitors inhibits the reaction [CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]]; Enzyme Inhibitors inhibits the reaction [Nitric Oxide results in decreased activity of CSF1 protein] [Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:8193360 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; Benzene promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; quinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7884313 |
|
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions |
ISO EXP |
[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide; CSF2 protein promotes the reaction [ITGB2 protein results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide] [CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide] [Benzene co-treated with Enzyme Inhibitors] promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; [CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; hydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; quinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7884313 PMID:8193360 PMID:8600936 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Ctf1 |
cardiotrophin 1 |
increases chemical synthesis |
ISO |
CTF1 protein results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:11304496 |
|
NCBI chr 7:127,311,848...127,317,360
Ensembl chr 7:127,311,908...127,317,364
|
|
G |
Cth |
cystathionase (cystathionine gamma-lyase) |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of CTH mRNA |
CTD |
PMID:14508194 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctsd |
cathepsin D |
increases secretion |
ISO |
Nitric Oxide results in increased secretion of CTSD protein |
CTD |
PMID:15040013 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
decreases secretion |
ISO |
Nitric Oxide results in decreased secretion of CXCL10 protein |
CTD |
PMID:13678430 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl12 |
chemokine (C-X-C motif) ligand 12 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of CXCL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
increases expression |
ISO |
Nitric Oxide results in increased expression of CXCL8 protein |
CTD |
PMID:10619828 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcr4 |
chemokine (C-X-C motif) receptor 4 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of CXCR4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cycs |
cytochrome c, somatic |
decreases secretion affects localization |
ISO |
Nitric Oxide results in decreased secretion of CYCS protein Nitric Oxide affects the localization of CYCS protein |
CTD |
PMID:10222263 PMID:10356289 PMID:10358093 PMID:16024610 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[CYP2E1 protein results in increased metabolism of Ethanol] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18845238 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Dab1 |
disabled 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of DAB1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041
|
|
G |
Ddah2 |
dimethylarginine dimethylaminohydrolase 2 |
multiple interactions |
ISO |
DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased abundance of Nitric Oxide]] |
CTD |
PMID:32135237 |
|
NCBI chr17:35,278,011...35,281,075
Ensembl chr17:35,278,011...35,281,071
|
|
G |
Ddc |
dopa decarboxylase |
increases activity |
ISO |
Nitric Oxide deficiency results in increased activity of DDC protein |
CTD |
PMID:7541690 |
|
NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144
|
|
G |
Dffb |
DNA fragmentation factor, beta subunit |
increases activity |
ISO |
Nitric Oxide results in increased activity of DFFB protein |
CTD |
PMID:15040013 |
|
NCBI chr 4:154,048,904...154,059,578
Ensembl chr 4:154,048,906...154,059,583
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization |
ISO |
Nitric Oxide affects the localization of DIABLO protein |
CTD |
PMID:15126337 |
|
NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of DUSP1 mRNA |
CTD |
PMID:9699677 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Ech1 |
enoyl coenzyme A hydratase 1, peroxisomal |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of ECH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:28,524,763...28,531,664
Ensembl chr 7:28,524,642...28,531,672
|
|
G |
Edn1 |
endothelin 1 |
increases chemical synthesis increases secretion decreases activity increases expression multiple interactions increases abundance decreases expression |
ISO EXP |
EDN1 protein results in increased chemical synthesis of Nitric Oxide Nitric Oxide results in increased secretion of EDN1 protein Nitric Oxide deficiency results in decreased activity of EDN1 protein Nitric Oxide deficiency results in increased expression of EDN1 mRNA [EDN1 protein results in increased activity of EDNRB protein] which results in increased abundance of Nitric Oxide; [EDN1 protein results in increased activity of NOS1 protein] which results in increased abundance of Nitric Oxide; BQ 788 inhibits the reaction [EDN1 protein results in increased abundance of Nitric Oxide]; Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]; S-methylthiocitrulline inhibits the reaction [EDN1 protein results in increased abundance of Nitric Oxide] Nitric Oxide results in decreased expression of EDN1 protein Nitric Oxide results in increased expression of EDN1 protein Nitric Oxide results in increased expression of EDN1 mRNA |
CTD |
PMID:11187978 PMID:15640287 PMID:15838368 PMID:16326922 PMID:16380457 PMID:16389725 PMID:16810074 PMID:20197249 PMID:20929026 More...
|
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
[EDN1 protein results in increased activity of EDNRB protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:16380457 |
|
NCBI chr14:104,052,051...104,083,248
Ensembl chr14:104,052,061...104,081,838
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of EEF1A1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:78,385,735...78,389,006
Ensembl chr 9:78,385,731...78,396,433
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of EEF1B2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:63,215,990...63,219,645
Ensembl chr 1:63,215,984...63,219,645
|
|
G |
Ehmt2 |
euchromatic histone lysine N-methyltransferase 2 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of EHMT2 protein |
CTD |
PMID:23546878 |
|
NCBI chr17:35,117,426...35,133,049
Ensembl chr17:35,117,445...35,133,028
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of EIF1A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:46,730,771...46,743,292
Ensembl chr18:46,730,768...46,749,523
|
|
G |
Eif2ak1 |
eukaryotic translation initiation factor 2 alpha kinase 1 |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [Mercury results in decreased activity of EIF2AK1 protein] |
CTD |
PMID:17689536 |
|
NCBI chr 5:143,803,530...143,839,535
Ensembl chr 5:143,803,543...143,841,069
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B, subunit 4 delta |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of EIF2B4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:31,344,902...31,350,483
Ensembl chr 5:31,344,902...31,350,774
|
|
G |
Eif3g |
eukaryotic translation initiation factor 3, subunit G |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of EIF3G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:20,805,645...20,809,886
Ensembl chr 9:20,805,645...20,809,919
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
EXP |
EPAS1 protein affects the reaction [Cobalt results in increased abundance of Nitric Oxide]; EPAS1 protein affects the reaction [Nickel results in increased abundance of Nitric Oxide] |
CTD |
PMID:23788631 |
|
NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Nitric Oxide |
CTD |
PMID:15816862 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18296501 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of EZH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:101,081,941...101,117,289
Ensembl chr11:101,081,941...101,117,289
|
|
G |
Ezr |
ezrin |
increases phosphorylation |
ISO |
Nitric Oxide deficiency results in increased phosphorylation of EZR protein |
CTD |
PMID:14732730 |
|
NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183
|
|
G |
F2 |
coagulation factor II |
multiple interactions increases abundance |
ISO |
arsenite inhibits the reaction [F2 protein results in increased abundance of Nitric Oxide]; F2 protein promotes the reaction [Heparin results in increased abundance of Nitric Oxide] |
CTD |
PMID:8408661 PMID:22244921 |
|
NCBI chr 2:91,442,742...91,466,802
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
Fas |
Fas (TNF receptor superfamily member 6) |
increases expression |
ISO |
Nitric Oxide results in increased expression of FAS mRNA; Nitric Oxide results in increased expression of FAS protein |
CTD |
PMID:15126337 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand (TNF superfamily, member 6) |
multiple interactions |
ISO |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] |
CTD |
PMID:10811113 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases abundance multiple interactions |
ISO |
FGF1 protein results in increased abundance of Nitric Oxide PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:16524372 |
|
NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525
|
|
G |
Fosb |
FBJ osteosarcoma oncogene B |
increases activity |
ISO |
Nitric Oxide results in increased activity of FOSB protein |
CTD |
PMID:15949472 |
|
NCBI chr 7:19,036,621...19,043,970
Ensembl chr 7:19,036,621...19,043,976
|
|
G |
Ftl1 |
ferritin light polypeptide 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of FTL1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions increases expression |
ISO EXP |
[7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat affects the localization of GAPDH protein] Nitric Oxide deficiency results in increased expression of GAPDH mRNA |
CTD |
PMID:15878706 PMID:20478973 |
|
NCBI chr 6:125,138,815...125,143,430
Ensembl chr 6:125,138,678...125,143,430
|
|
G |
Gata5 |
GATA binding protein 5 |
multiple interactions increases expression increases response to substance |
ISO |
GATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]; GATA5 protein promotes the reaction [Nitric Oxide results in increased expression of BCL2L1 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 protein] Nitric Oxide results in increased expression of GATA5 mRNA; Nitric Oxide results in increased expression of GATA5 protein GATA5 protein results in increased susceptibility to Nitric Oxide |
CTD |
PMID:25726415 |
|
NCBI chr 2:179,966,881...179,977,296
Ensembl chr 2:179,966,926...179,976,492
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of GCLC mRNA; Nitric Oxide deficiency results in decreased expression of GCLC protein |
CTD |
PMID:19631198 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
ISO |
GCLM gene SNP affects the abundance of and affects the activity of and affects the susceptibility to Nitric Oxide |
CTD |
PMID:12975258 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gdi2 |
guanosine diphosphate (GDP) dissociation inhibitor 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of GDI2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr13:3,588,075...3,616,261
Ensembl chr13:3,588,063...3,617,871
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of GFAP protein |
CTD |
PMID:15763998 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of GJA1 mRNA; Nitric Oxide deficiency results in decreased expression of GJA1 protein; Nitric Oxide results in decreased expression of GJA1 protein |
CTD |
PMID:10397678 PMID:11856964 PMID:20004189 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Glb1 |
galactosidase, beta 1 |
decreases activity |
ISO |
Nitric Oxide results in decreased activity of GLB1 protein |
CTD |
PMID:17075048 |
|
NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
|
|
G |
Gltp |
glycolipid transfer protein |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GLTP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:114,807,551...114,828,996
Ensembl chr 5:114,807,459...114,829,045
|
|
G |
Gm20348 |
predicted gene, 20348 |
increases expression |
ISO |
Nitric Oxide results in increased expression of TP53I3 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr12:4,860,475...4,867,155
Ensembl chr12:4,860,494...4,867,142
|
|
G |
Gpc1 |
glypican 1 |
increases nitrosation multiple interactions |
EXP |
Nitric Oxide results in increased nitrosation of GPC1 protein [Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form; Zinc promotes the reaction [[Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form] |
CTD |
PMID:15677459 PMID:16923158 |
|
NCBI chr 1:92,759,367...92,787,933
Ensembl chr 1:92,759,367...92,788,501
|
|
G |
Gpi1 |
glucose-6-phosphate isomerase 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GPI1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:33,900,752...33,929,761
Ensembl chr 7:33,900,755...33,929,761
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects metabolic processing multiple interactions |
EXP |
GPX1 protein affects the metabolism of Nitric Oxide GPX1 protein affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide] |
CTD |
PMID:11498278 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GPX2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression multiple interactions |
EXP ISO |
Nitric Oxide deficiency results in increased expression of GPX3 mRNA Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of GPX3 mRNA] |
CTD |
PMID:15878706 PMID:21983654 |
|
NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of GRB2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:115,534,871...115,599,423
Ensembl chr11:115,534,871...115,599,423
|
|
G |
Gsn |
gelsolin |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GSN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:35,146,371...35,197,914
Ensembl chr 2:35,146,392...35,197,904
|
|
G |
Gsr |
glutathione reductase |
increases expression multiple interactions affects activity |
ISO |
Nitric Oxide deficiency results in increased expression of GSR protein tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of GSR protein] Nitric Oxide deficiency affects the activity of GSR protein |
CTD |
PMID:15925750 PMID:19631198 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gstm1 |
glutathione S-transferase, mu 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GSTM1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289
|
|
G |
Gstm2 |
glutathione S-transferase, mu 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of GSTM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769
|
|
G |
Gucy1a1 |
guanylate cyclase 1, soluble, alpha 1 |
multiple interactions increases response to substance |
ISO |
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]] GUCY1A1 gene mutant form results in increased susceptibility to Nitric Oxide |
CTD |
PMID:11744065 PMID:25373139 |
|
NCBI chr 3:81,999,734...82,053,253
Ensembl chr 3:81,999,734...82,053,096
|
|
G |
Gucy1b1 |
guanylate cyclase 1, soluble, beta 1 |
multiple interactions |
ISO |
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]] |
CTD |
PMID:11744065 |
|
NCBI chr 3:81,939,311...81,982,018
Ensembl chr 3:81,939,313...81,981,996
|
|
G |
Gulo |
gulonolactone (L-) oxidase |
multiple interactions |
EXP |
[GULO protein co-treated with NOS3 protein] results in increased abundance of Nitric Oxide |
CTD |
PMID:16737683 |
|
NCBI chr14:66,224,235...66,246,703
Ensembl chr14:66,224,235...66,246,656
|
|
G |
H2-Eb1 |
histocompatibility 2, class II antigen E beta |
increases abundance |
ISO |
HLA-DRB1 protein results in increased abundance of Nitric Oxide |
CTD |
PMID:17075829 |
|
NCBI chr17:34,524,841...34,535,648
Ensembl chr17:34,524,841...34,535,648
|
|
G |
Hadh |
hydroxyacyl-Coenzyme A dehydrogenase |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of HADH mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:131,027,068...131,065,750
Ensembl chr 3:131,027,068...131,065,750
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of HAVCR1 protein |
CTD |
PMID:19834340 |
|
NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
|
|
G |
Hbs1l |
Hbs1-like (S. cerevisiae) |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of HBS1L mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:21,171,876...21,244,788
Ensembl chr10:21,171,878...21,244,797
|
|
G |
Hcrt |
hypocretin |
increases abundance |
ISO |
HCRT results in increased abundance of Nitric Oxide |
CTD |
PMID:18378017 |
|
NCBI chr11:100,652,519...100,653,757
Ensembl chr11:100,651,895...100,653,757
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions |
ISO |
Nitric Oxide results in decreased stability of and results in decreased expression of HIF1A protein; U 0126 inhibits the reaction [Nitric Oxide results in decreased degradation of and results in increased activity of HIF1A protein] |
CTD |
PMID:16310922 PMID:18424783 |
|
NCBI chr12:73,948,098...73,994,328
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases response to substance increases expression affects activity multiple interactions affects response to substance |
ISO EXP |
HMOX1 protein results in decreased susceptibility to Nitric Oxide Nitric Oxide results in increased expression of HMOX1 protein Nitric Oxide affects the activity of HMOX1 protein Nitric Oxide results in increased expression of HMOX1 mRNA; Nitric Oxide results in increased expression of HMOX1 protein HMOX1 protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide]; Nitric Oxide results in increased stability of and results in increased expression of HMOX1 mRNA HMOX1 protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:9699677 PMID:15220209 PMID:17020887 PMID:17401437 PMID:18178725 PMID:19183270 PMID:20888885 PMID:21690482 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hprt |
hypoxanthine guanine phosphoribosyl transferase |
increases mutagenesis |
ISO |
Nitric Oxide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:22303861 PMID:28454271 |
|
NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 protein |
CTD |
PMID:19320461 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspa8 |
heat shock protein 8 |
multiple interactions |
ISO |
[sodium arsenite results in increased expression of HSPA8 protein] which results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:10216529 |
|
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
|
|
G |
Hyal2 |
hyaluronoglucosaminidase 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of HYAL2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:107,445,085...107,449,977
Ensembl chr 9:107,445,144...107,449,978
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of ICAM1 protein]] |
CTD |
PMID:14762100 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
Nitric Oxide binds to and affects the folding of and results in increased degradation of and results in decreased activity of IDO1 protein |
CTD |
PMID:16834326 |
|
NCBI chr 8:25,074,149...25,086,968
Ensembl chr 8:25,074,152...25,087,025
|
|
G |
Ifnb1 |
interferon beta 1, fibroblast |
multiple interactions |
EXP |
[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; Dexamethasone inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; tocotrienol, delta inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:22185406 |
|
NCBI chr 4:88,440,262...88,441,031
Ensembl chr 4:88,440,262...88,441,011
|
|
G |
Ifng |
interferon gamma |
increases secretion increases chemical synthesis multiple interactions increases abundance |
ISO EXP |
Nitric Oxide results in increased secretion of IFNG protein IFNG protein results in increased chemical synthesis of Nitric Oxide 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; 5-nitro-2-(3-phenylpropylamino)benzoic acid inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides co-treated with quinone] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lead acetate results in increased abundance of Lead] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased secretion of Nitric Oxide; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Aminosalicylic Acids inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; Capsaicin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Capsaicin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; capsazepine inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; catalpol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; chromous chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltiprotoporphyrin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cupric chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Dexamethasone inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Dexamethasone inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Diquat promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; Dronabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased abundance of Nitric Oxide]; Estriol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; GPX1 protein affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; GW 1929 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Ibuprofen inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; IFNG promotes the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with Benzene] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with hydroquinone] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Indomethacin inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; JAK2 protein promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Lipopolysaccharides promotes the reaction [[IFNG protein co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide]; Lipopolysaccharides promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; MK 473 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NS 1652 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; NS-3728 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; pimagedine inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; pimagedine inhibits the reaction [Lipopolysaccharides promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; resiniferatoxin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; resiniferatoxin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Sulfasalazine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Tamoxifen inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; TBE 31 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; tocotrienol, delta inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; U 0126 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; zinc chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]] [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Clofibrate inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; CSF1 protein promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; Gemfibrozil inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; morin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; pterostilbene inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] IFNG protein results in increased abundance of Nitric Oxide; IFNG results in increased abundance of Nitric Oxide (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with Manganese] results in decreased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [pyrazolanthrone co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [SB 203580 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [U 0126 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Apigenin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Cannabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Deoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; IFNG promotes the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; Indomethacin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Nitric Oxide affects the susceptibility to [IFNG protein co-treated with Lipopolysaccharides]; Ozone promotes the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Polyphenols inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; Rimonabant inhibits the reaction [Cannabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; S-methylisothiopseudouronium inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; U 0126 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7519435 PMID:7689037 PMID:7884313 PMID:8193360 PMID:8341679 PMID:8765472 PMID:8903404 PMID:8975779 PMID:8979148 PMID:10205001 PMID:10607705 PMID:10909967 PMID:11020457 PMID:11063824 PMID:11080519 PMID:11282106 PMID:11498278 PMID:11520904 PMID:11529938 PMID:11727767 PMID:11907163 PMID:12244038 PMID:12612912 PMID:12620498 PMID:12847270 PMID:12911628 PMID:13678430 PMID:14530214 PMID:14617770 PMID:14623498 PMID:15177305 PMID:16168523 PMID:16307444 PMID:16366677 PMID:16488514 PMID:16968468 PMID:18090225 PMID:18206661 PMID:19393675 PMID:19446535 PMID:19825429 PMID:20424383 PMID:21361338 PMID:21943492 PMID:22185406 PMID:22461696 PMID:22698256 PMID:23164921 PMID:23362215 PMID:24412304 PMID:25766886 PMID:28242320 PMID:34352350 More...
|
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il10 |
interleukin 10 |
decreases secretion |
ISO |
Nitric Oxide results in decreased secretion of IL10 protein |
CTD |
PMID:13678430 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il12b |
interleukin 12b |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of IL12B protein |
CTD |
PMID:13678430 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il12rb2 |
interleukin 12 receptor, beta 2 |
increases expression |
EXP |
Nitric Oxide results in increased expression of IL12RB2 mRNA |
CTD |
PMID:12451176 |
|
NCBI chr 6:67,263,914...67,353,277
Ensembl chr 6:67,268,302...67,353,172
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases abundance |
ISO |
[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:16968468 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases chemical synthesis increases abundance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with Fatty Acids, Nonesterified] results in increased chemical synthesis of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; bisphenol A inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Clofibrate inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Cytochalasin B inhibits the reaction [Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; Cytochalasin B inhibits the reaction [Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; Dactinomycin inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; Estradiol inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Gemfibrozil inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; IL1B protein promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; IL4 protein inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Leflunomide inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; LEP protein affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Methotrexate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of ICAM1 protein]]; Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of SELE protein]]; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; pimagedine inhibits the reaction [Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; sauchinone inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Triglycerides affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Troglitazone inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Troglitazone inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide] [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; IL1B protein promotes the reaction [Cobalt results in increased abundance of Nitric Oxide]; IL1B protein promotes the reaction [Nickel results in increased abundance of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA] IL1B protein results in increased abundance of Nitric Oxide; IL1B results in increased abundance of Nitric Oxide [Enzyme Inhibitors results in decreased abundance of Nitric Oxide] inhibits the reaction [IL1B protein results in decreased secretion of INS1 protein]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; Active Hexose Correlated Compound inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Active Hexose Correlated Compound inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Apigenin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; IL1B protein affects the reaction [AVP protein affects the metabolism of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SOD2 protein inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Vitamin E inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:7519435 PMID:8903404 PMID:8982730 PMID:9312173 PMID:9576743 PMID:9698594 PMID:10365824 PMID:10909967 PMID:11229466 PMID:11286988 PMID:11457450 PMID:11530235 PMID:12115740 PMID:12244038 PMID:12384474 PMID:14617770 PMID:14623498 PMID:14762100 PMID:14996425 PMID:15144122 PMID:15223066 PMID:16393772 PMID:16492401 PMID:17109745 PMID:17712145 PMID:18026701 PMID:18078833 PMID:18090225 PMID:19347386 PMID:19393675 PMID:20600708 PMID:21171372 PMID:21943492 PMID:23788631 PMID:24425765 PMID:24878381 PMID:25766886 PMID:29356224 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO EXP |
IL4 protein inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide] IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:12115740 PMID:12612912 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
multiple interactions decreases secretion |
ISO |
[IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide Nitric Oxide results in decreased secretion of IL5 protein |
CTD |
PMID:13678430 PMID:18206661 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of IL6 protein] which results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of IL6 protein] |
CTD |
PMID:20708382 PMID:21983654 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins2 |
insulin II |
increases secretion decreases secretion multiple interactions increases chemical synthesis |
ISO |
INS protein results in increased secretion of Nitric Oxide INS protein results in decreased secretion of Nitric Oxide [INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide; [Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide]; Orotic Acid inhibits the reaction [INS protein results in increased abundance of Nitric Oxide]; Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]; PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide]; quercetin 3-O-glucuronide inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]]; Quercetin inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]]; resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]; SIRT1 protein affects the reaction [INS protein results in increased secretion of Nitric Oxide]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]]; Sodium Salicylate inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]] |
CTD |
PMID:20960276 PMID:23504962 PMID:25601987 PMID:26364587 PMID:28951307 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions increases abundance |
ISO |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP1A protein]; Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP2A protein] ITGB2 protein results in increased abundance of Nitric Oxide [CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide; [ITGB2 protein results in increased susceptibility to Ozone] which results in increased abundance of Nitric Oxide; CSF2 protein promotes the reaction [ITGB2 protein results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:8600936 PMID:16963453 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Itgb3 |
integrin beta 3 |
increases expression |
ISO |
Nitric Oxide results in increased expression of ITGB3 protein |
CTD |
PMID:21332719 |
|
NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302
|
|
G |
Jak1 |
Janus kinase 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of JAK1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression |
EXP |
JAK2 protein promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of JAK2 mRNA |
CTD |
PMID:12847270 PMID:15878706 |
|
NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480
|
|
G |
Jun |
jun proto-oncogene |
increases activity |
ISO |
Nitric Oxide results in increased activity of JUN protein |
CTD |
PMID:15949472 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
increases activity |
ISO |
Nitric Oxide results in increased activity of JUNB protein |
CTD |
PMID:15949472 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Kdm1a |
lysine (K)-specific demethylase 1A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM1A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 4:136,277,844...136,330,127
Ensembl chr 4:136,277,851...136,330,034
|
|
G |
Kdm3a |
lysine (K)-specific demethylase 3A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM3A mRNA; Nitric Oxide results in increased expression of KDM3A protein |
CTD |
PMID:23546878 |
|
NCBI chr 6:71,565,954...71,609,963
Ensembl chr 6:71,565,956...71,609,974
|
|
G |
Kdm3b |
KDM3B lysine (K)-specific demethylase 3B |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM3B mRNA |
CTD |
PMID:23546878 |
|
NCBI chr18:34,910,061...34,972,423
Ensembl chr18:34,910,100...34,971,713
|
|
G |
Kdm4a |
lysine (K)-specific demethylase 4A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 4:117,994,154...118,037,242
Ensembl chr 4:117,994,154...118,037,240
|
|
G |
Kdm4b |
lysine (K)-specific demethylase 4B |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4B mRNA |
CTD |
PMID:23546878 |
|
NCBI chr17:56,632,975...56,710,774
Ensembl chr17:56,633,062...56,709,870
|
|
G |
Kdm4c |
lysine (K)-specific demethylase 4C |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4C mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 4:74,160,734...74,324,101
Ensembl chr 4:74,160,734...74,324,097
|
|
G |
Kdm4d |
lysine (K)-specific demethylase 4D |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4D mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 9:14,373,844...14,411,818
Ensembl chr 9:14,373,844...14,411,778
|
|
G |
Kdm7a |
lysine (K)-specific demethylase 7A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM7A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 6:39,113,554...39,183,707
Ensembl chr 6:39,113,557...39,183,723
|
|
G |
Klk1 |
kallikrein 1 |
increases abundance multiple interactions |
ISO |
KLK1 protein results in increased abundance of Nitric Oxide icatibant inhibits the reaction [KLK1 protein results in increased abundance of Nitric Oxide]; KLK1 protein inhibits the reaction [Gentamicins results in decreased abundance of Nitric Oxide] |
CTD |
PMID:16401625 |
|
NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042
|
|
G |
Kng2 |
kininogen 2 |
increases abundance multiple interactions increases secretion affects abundance |
ISO EXP |
KNG1 protein results in increased abundance of Nitric Oxide [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide; Lipopolysaccharides promotes the reaction [KNG1 protein modified form results in increased chemical synthesis of Nitric Oxide] KNG1 protein results in increased secretion of Nitric Oxide KNG1 affects the abundance of Nitric Oxide PD 123319 affects the reaction [KNG1 affects the abundance of Nitric Oxide] |
CTD |
PMID:10535458 PMID:16514058 PMID:16733097 PMID:29775649 |
|
NCBI chr16:22,804,602...22,847,851
Ensembl chr16:22,804,604...22,848,232
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
LEP protein affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:9312173 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lif |
leukemia inhibitory factor |
multiple interactions |
EXP |
LIF protein affects the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased abundance of Nitric Oxide]]; LIF protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased abundance of Nitric Oxide] |
CTD |
PMID:23409146 |
|
NCBI chr11:4,207,568...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Ltf |
lactotransferrin |
increases chemical synthesis decreases activity |
ISO |
LTF protein results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in decreased activity of LTF protein |
CTD |
PMID:14563657 |
|
NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation decreases expression |
ISO |
Nitric Oxide affects the reaction [Ditiocarb results in increased phosphorylation of MAPK1 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK1 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein] Nitric Oxide results in decreased phosphorylation of MAPK1 protein Nitric Oxide results in decreased expression of MAPK1 protein |
CTD |
PMID:14713289 PMID:15640287 PMID:16389725 PMID:16575906 PMID:16603213 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation decreases expression |
ISO |
Nitric Oxide affects the reaction [Ditiocarb results in increased phosphorylation of MAPK3 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK3 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein] Nitric Oxide results in decreased phosphorylation of MAPK3 protein Nitric Oxide results in decreased expression of MAPK3 protein |
CTD |
PMID:14713289 PMID:15640287 PMID:16389725 PMID:16575906 PMID:16603213 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mbp |
myelin basic protein |
increases abundance multiple interactions |
ISO |
MBP protein results in increased abundance of Nitric Oxide Testosterone inhibits the reaction [MBP protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:18579221 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mef2a |
myocyte enhancer factor 2A |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of MEF2A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:66,880,911...67,026,435
Ensembl chr 7:66,880,911...67,022,606
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; [S-nitrosocysteine results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; Dithiothreitol inhibits the reaction [[1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein]; Dithiothreitol inhibits the reaction [[S-nitrosocysteine results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein]; Dithiothreitol inhibits the reaction [[S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein] |
CTD |
PMID:16386761 |
|
NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
ISO |
Nitric Oxide results in decreased expression of MMP2 protein Nitric Oxide results in increased expression of and results in increased activity of MMP2 protein |
CTD |
PMID:16575906 PMID:18796497 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
Nitric Oxide results in increased expression of MMP9 mRNA |
CTD |
PMID:20197249 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
increases expression multiple interactions increases oxidation |
ISO |
Nitric Oxide results in increased expression of MPO protein 4-amino-TEMPO inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [1,6-diaminohexane binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Cadaverine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [ethylenediamine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Putrescine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Spermine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [trimethylenediamine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide] [Paraquat co-treated with Nitric Oxide] results in increased activity of MPO protein |
CTD |
PMID:10706834 PMID:15820443 PMID:34085520 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mrps7 |
mitchondrial ribosomal protein S7 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of MRPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:115,494,966...115,498,862
Ensembl chr11:115,494,751...115,498,862
|
|
G |
Msn |
moesin |
increases phosphorylation |
ISO |
Nitric Oxide deficiency results in increased phosphorylation of MSN protein |
CTD |
PMID:14732730 |
|
NCBI chr X:95,139,651...95,212,159
Ensembl chr X:95,139,648...95,212,158
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
affects activity affects expression |
ISO |
Nitric Oxide affects the activity of COX1 protein Nitric Oxide affects the expression of COX1 mRNA |
CTD |
PMID:17936468 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
EXP |
Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA] |
CTD |
PMID:14617770 |
|
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
|
|
G |
Mt2 |
metallothionein 2 |
multiple interactions |
EXP |
Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA] |
CTD |
PMID:14617770 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
ISO |
MT3 protein results in decreased susceptibility to Nitric Oxide |
CTD |
PMID:10854270 |
|
NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]] |
CTD |
PMID:22363816 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Myh6 |
myosin, heavy polypeptide 6, cardiac muscle, alpha |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of MYH6 mRNA |
CTD |
PMID:16326922 |
|
NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384
|
|
G |
Myh7 |
myosin, heavy polypeptide 7, cardiac muscle, beta |
increases expression multiple interactions |
ISO |
Nitric Oxide deficiency results in increased expression of MYH7 mRNA Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083
|
|
G |
Ndn |
necdin, MAGE family member |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of NDN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:61,998,025...61,999,676
Ensembl chr 7:61,996,317...62,000,010
|
|
G |
Ndrg1 |
N-myc downstream regulated gene 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of NDRG1 mRNA; Nitric Oxide results in increased expression of NDRG1 protein |
CTD |
PMID:21976667 |
|
NCBI chr15:66,801,167...66,841,490
Ensembl chr15:66,801,167...66,841,489
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of NDUFA13 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:70,346,813...70,355,208
Ensembl chr 8:70,346,830...70,355,208
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
NFKB1 protein promotes the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:12162464 |
|
NCBI chr 3:135,290,416...135,397,728
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]] |
CTD |
PMID:16168523 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK1 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK3 protein] |
CTD |
PMID:14713289 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nos1 |
nitric oxide synthase 1, neuronal |
multiple interactions increases chemical synthesis decreases expression |
EXP ISO |
PLAT protein affects the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of NOS1 protein [Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide]; [Cisplatin results in increased expression of NOS1 mRNA] which results in increased abundance of Nitric Oxide; [EDN1 protein results in increased activity of NOS1 protein] which results in increased abundance of Nitric Oxide; [Formaldehyde results in increased expression of NOS1 protein] which results in increased abundance of Nitric Oxide; [NOS1 protein results in increased reduction of Trinitrotoluene] which results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:15223068 PMID:15249212 PMID:16380457 PMID:17098364 PMID:18195371 PMID:19038279 PMID:23359814 PMID:24184442 PMID:25766886 More...
|
|
NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
increases abundance affects abundance increases chemical synthesis decreases expression affects expression multiple interactions increases expression |
ISO EXP |
NOS2 protein results in increased abundance of Nitric Oxide NOS2 promoter polymorphism affects the abundance of Nitric Oxide NOS2 protein results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in decreased expression of NOS2 protein Nitric Oxide deficiency affects the expression of NOS2 protein [Endotoxins results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Ethanol results in decreased expression of and results in decreased activity of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Formaldehyde results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Fructose results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Gentamicins results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Indomethacin results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Isoproterenol results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased susceptibility to endothelium-dependent hyperpolarization factor; [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; Active Hexose Correlated Compound inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Endotoxins inhibits the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; natakalim inhibits the reaction [[Isoproterenol results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of NOS2 mRNA]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; wuzi yanzong analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] 1,2-naphthoquinone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; [3,5-dimethoxy-4'-hydroxystilbene results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]] which results in decreased abundance of Nitric Oxide; [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA; [Acetaminophen results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Aspirin results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]] which results in increased chemical synthesis of Nitric Oxide; [Cisplatin results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [cobaltous chloride results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide; [diferuloylputrescine results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [ferulic acid results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide; [Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Nicotine results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased expression of TJP1 mRNA; [Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [p-coumaric acid results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [pimobendan results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Plant Extracts results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [prunetin results in decreased expression of NOS2 mRNA] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased chemical synthesis of Nitric Oxide]; [Putrescine metabolite results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Quercetin results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Selenium inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]] which results in decreased chemical synthesis of Nitric Oxide; [Sodium Salicylate results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Thiourea analog results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Zoledronic Acid results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; bepafant inhibits the reaction [[Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; bisphenol A inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Caffeine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Capsaicin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Capsaicin inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Carthamus yellow inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Chalcone analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2] which results in increased abundance of Nitric Oxide]; chromous chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Cilostazol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cupric chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Cyclosporine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; diphenylmethyl selenocyanate inhibits the reaction [[Cisplatin results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Drugs, Chinese Herbal inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; ent-1,3,6,11-tetrahydroxykaur-16-ene-15-one 3,11-diacetate inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide]]; ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; flavokawain A inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Fluoxetine analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Ginkgo biloba extract inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; GW 1929 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; hinokiresinol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; naringenin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; NFKB1 protein promotes the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; nimesulide inhibits the reaction [bepafant inhibits the reaction [[Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]]; Nitroprusside inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; praeruptorin A inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Pyrazines inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Quercetin analog inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Quercetin inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; quercetin pentaacetate inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; resiniferatoxin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; resiniferatoxin inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Resveratrol inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Resveratrol metabolite inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Rutin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; STAT1 protein promotes the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; timosaponin BIII inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; zinc chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]] [[Fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [[Particulate Matter results in increased abundance of Ammonium Compounds] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [[Particulate Matter results in increased abundance of Carbon] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [[Particulate Matter results in increased abundance of Nitrates] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [Acetaldehyde results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Ethanol results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [Fluvastatin results in increased abundance of Nitric Oxide]; [Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; [NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; [Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Resveratrol results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Trichloroethylene results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Vehicle Emissions results in increased abundance of Air Pollutants] inhibits the reaction [NOS2 promoter polymorphism affects the abundance of Nitric Oxide]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Cyclosporine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein]; Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; HMOX1 protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide]; Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; IL1B protein promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; Leflunomide inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; lornoxicam inhibits the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Methotrexate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nicotine promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; Peptides inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; XDH protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide] Nitric Oxide results in increased expression of NOS2 mRNA; Nitric Oxide results in increased expression of NOS2 protein |
CTD |
PMID:7519435 PMID:7705308 PMID:8193360 PMID:8652180 PMID:8975779 PMID:8982730 PMID:9288130 PMID:9530173 PMID:9706149 PMID:9743513 PMID:9755104 PMID:9788894 PMID:10022268 PMID:10086329 PMID:10090849 PMID:10188978 PMID:10193745 PMID:10450786 PMID:10860828 PMID:10909967 PMID:11020457 PMID:11173986 PMID:11286988 PMID:11500931 PMID:11518563 PMID:11530235 PMID:11919077 PMID:12060119 PMID:12133974 PMID:12144947 PMID:12162464 PMID:12175900 PMID:12612912 PMID:12847270 PMID:12860292 PMID:14530214 PMID:15242784 PMID:15249212 PMID:15364003 PMID:15529353 PMID:16168523 PMID:16376947 PMID:16389574 PMID:16393772 PMID:16927020 PMID:16944022 PMID:17067557 PMID:17135264 PMID:17135361 PMID:17312373 PMID:17448908 PMID:17467989 PMID:17541474 PMID:17570326 PMID:17630198 PMID:17651055 PMID:17712145 PMID:17719164 PMID:18073202 PMID:18078833 PMID:18369347 PMID:18481332 PMID:18507870 PMID:18550010 PMID:18796497 PMID:18838107 PMID:18845238 PMID:19631198 PMID:19818098 PMID:20004183 PMID:20023007 PMID:20035746 PMID:20417174 PMID:20527891 PMID:20558268 PMID:20708382 PMID:20712904 PMID:20842678 PMID:20848677 PMID:20888885 PMID:20942565 PMID:20955790 PMID:21139339 PMID:21256160 PMID:21284090 PMID:21464294 PMID:21467642 PMID:21893401 PMID:21926162 PMID:21983654 PMID:22076046 PMID:22101131 PMID:22155221 PMID:22224493 PMID:22227475 PMID:22251620 PMID:22342441 PMID:22366099 PMID:22472292 PMID:22974838 PMID:23106696 PMID:23359814 PMID:23597450 PMID:23727179 PMID:23774260 PMID:24161485 PMID:24412304 PMID:24964743 PMID:25766886 PMID:25870319 PMID:26045775 PMID:26372312 PMID:26714306 PMID:27174236 PMID:30322157 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
decreases chemical synthesis multiple interactions increases chemical synthesis affects chemical synthesis decreases expression affects expression increases abundance |
ISO EXP |
NOS3 gene mutant form results in decreased chemical synthesis of Nitric Oxide 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]]; [[resveratrol results in increased activity of PPARA protein] which results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Estradiol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; [Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide; [Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of RCN1 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of TXNDC5 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 protein; [Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; [Orotic Acid inhibits the reaction [Metformin results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; [puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [resveratrol results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [resveratrol results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide; [resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Trichloroethylene results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; Amiodarone promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; desethylamiodarone promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; fulvestrant inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; icariin promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; NOX5 protein promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide]; resveratrol inhibits the reaction [[Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide]; rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; SOD1 protein inhibits the reaction [Nitric Oxide results in decreased activity of NOS3 protein]; Stilbenes inhibits the reaction [[Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide]; Tretinoin promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; U 0126 inhibits the reaction [[resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide]; W 7 inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]] NOS3 protein affects the chemical synthesis of Nitric Oxide [Bezafibrate results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [GULO protein co-treated with NOS3 protein] results in increased abundance of Nitric Oxide; [Resveratrol results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; dorsomorphin inhibits the reaction [[Bezafibrate results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of NOS3 mRNA; Nitric Oxide deficiency results in decreased expression of NOS3 protein Nitric Oxide deficiency affects the expression of NOS3 protein [Sildenafil Citrate results in increased expression of NOS3 protein] which results in increased secretion of Nitric Oxide; AGT protein alternative form promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; Enalapril inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of NOS3 mRNA]; Thioacetamide promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide] NOS3 protein results in increased abundance of Nitric Oxide |
CTD |
PMID:10445667 PMID:11740345 PMID:12270858 PMID:12489993 PMID:15207323 PMID:15249212 PMID:16043647 PMID:16197366 PMID:16479044 PMID:16737683 PMID:17499557 PMID:17719164 PMID:18296501 PMID:18556569 PMID:18716157 PMID:18990443 PMID:19011239 PMID:19320461 PMID:19631198 PMID:19696404 PMID:19767878 PMID:19845545 PMID:20020783 PMID:20562903 PMID:20675566 PMID:21499286 PMID:21791144 PMID:21884717 PMID:21983654 PMID:22314268 PMID:22358095 PMID:24184442 PMID:25601987 More...
|
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of NPC1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:12,322,751...12,369,851
Ensembl chr18:12,322,749...12,369,457
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions increases expression |
ISO |
Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPA mRNA] Nitric Oxide deficiency results in increased expression of NPPA mRNA; Nitric Oxide deficiency results in increased expression of NPPA protein |
CTD |
PMID:10397678 PMID:12198334 PMID:14700747 PMID:15177930 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nppb |
natriuretic peptide type B |
multiple interactions increases expression |
ISO |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]; Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA] Nitric Oxide deficiency results in increased expression of NPPB mRNA; Nitric Oxide deficiency results in increased expression of NPPB protein |
CTD |
PMID:12198334 PMID:16326922 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of NR2F2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:70,001,694...70,016,494
Ensembl chr 7:70,001,692...70,016,483
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of NR4A1 mRNA |
CTD |
PMID:10460269 |
|
NCBI chr15:101,151,788...101,172,676
Ensembl chr15:101,152,150...101,172,676
|
|
G |
Nupr1 |
nuclear protein transcription regulator 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of NUPR1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
|
|
G |
Ocln |
occludin |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of OCLN protein |
CTD |
PMID:15763998 |
|
NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226
|
|
G |
P4ha1 |
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of P4HA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:59,159,019...59,209,126
Ensembl chr10:59,159,118...59,209,126
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions increases cleavage |
ISO EXP |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] PARP1 gene mutant form inhibits the reaction [S100B protein results in increased secretion of Nitric Oxide] Nitric Oxide results in increased cleavage of PARP1 protein |
CTD |
PMID:10811113 PMID:15126337 PMID:16024610 PMID:27444121 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PDCD6IP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:113,480,812...113,537,457
Ensembl chr 9:113,480,812...113,537,327
|
|
G |
Pde5a |
phosphodiesterase 5A, cGMP-specific |
increases expression affects response to substance |
ISO |
Nitric Oxide results in increased expression of PDE5A mRNA; Nitric Oxide results in increased expression of PDE5A protein PDE5A protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:19374906 |
|
NCBI chr 3:122,522,807...122,653,023
Ensembl chr 3:122,522,596...122,653,023
|
|
G |
Phf8 |
PHD finger protein 8 |
increases expression |
ISO |
Nitric Oxide results in increased expression of PHF8 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr X:150,303,621...150,416,855
Ensembl chr X:150,303,668...150,416,855
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
multiple interactions |
ISO |
PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide] |
CTD |
PMID:25601987 |
|
NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
multiple interactions |
ISO |
Nitric Oxide affects the reaction [Ditiocarb results in increased expression of PLA2G4A mRNA]; Nitric Oxide affects the reaction [Ditiocarb results in increased expression of PLA2G4A protein] |
CTD |
PMID:16603213 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Plat |
plasminogen activator, tissue |
multiple interactions increases secretion |
EXP |
PLAT protein affects the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] PLAT protein results in increased secretion of Nitric Oxide |
CTD |
PMID:18195371 |
|
NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Pms2 |
PMS1 homolog2, mismatch repair system component |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of PMS2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:143,846,379...143,922,538
Ensembl chr 5:143,846,782...143,870,786 Ensembl chr 5:143,846,782...143,870,786
|
|
G |
Pnoc |
prepronociceptin |
decreases activity |
ISO |
Nitric Oxide deficiency results in decreased activity of PNOC protein |
CTD |
PMID:10794074 |
|
NCBI chr14:65,638,122...65,663,130
Ensembl chr14:65,638,122...65,662,921
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
multiple interactions decreases abundance increases secretion |
ISO |
CRH protein affects the reaction [Nitric Oxide results in increased secretion of POMC protein alternative form] POMC protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:10460269 PMID:11193135 PMID:11703388 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects activity multiple interactions increases expression |
ISO |
Nitric Oxide affects the activity of PPARA protein [[resveratrol results in increased activity of PPARA protein] which results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide [Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased abundance of Nitric Oxide; [Clofibrate binds to and results in increased activity of PPARA protein] which results in increased abundance of Nitric Oxide; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in increased expression of PPARA protein] Nitric Oxide deficiency results in increased expression of PPARA mRNA; Nitric Oxide deficiency results in increased expression of PPARA protein |
CTD |
PMID:15018640 PMID:16054168 PMID:16411023 PMID:19834340 PMID:21791144 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
[rosiglitazone binds to and affects the activity of PPARG protein] which results in increased abundance of Nitric Oxide [1,1-bis(3'-indolyl)-1-(4-trifluoromethylphenyl)methane binds to and results in increased activity of PPARG protein] inhibits the reaction [Manganese results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; GW 1929 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide] |
CTD |
PMID:12847270 PMID:16527820 PMID:17063326 PMID:18041089 |
|
NCBI chr 6:115,337,840...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppm1d |
protein phosphatase 1D magnesium-dependent, delta isoform |
increases expression |
ISO |
Nitric Oxide results in increased expression of PPM1D mRNA |
CTD |
PMID:15126337 |
|
NCBI chr11:85,202,080...85,237,897
Ensembl chr11:85,202,070...85,237,892
|
|
G |
Ppm1g |
protein phosphatase 1G (formerly 2C), magnesium-dependent, gamma isoform |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PPM1G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:31,360,012...31,377,889
Ensembl chr 5:31,360,008...31,378,031
|
|
G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isoform |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PPP3CA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:136,375,778...136,643,488
Ensembl chr 3:136,375,885...136,643,488
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PPP5C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:16,738,565...16,761,839
Ensembl chr 7:16,738,565...16,761,849
|
|
G |
Prdm2 |
PR domain containing 2, with ZNF domain |
increases expression |
ISO |
Nitric Oxide results in increased expression of PRDM2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 4:142,833,961...142,939,560
Ensembl chr 4:142,833,961...142,939,565
|
|
G |
Prim2 |
DNA primase, p58 subunit |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PRIM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:33,492,889...33,708,875
Ensembl chr 1:33,492,891...33,708,876
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
ISO |
PRKAA1 protein affects the reaction [Fenofibrate results in increased abundance of Nitric Oxide] |
CTD |
PMID:20580385 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
Nitric Oxide deficiency promotes the reaction [Brimonidine Tartrate affects the localization of PRKCA protein] |
CTD |
PMID:12388232 |
|
NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [Brimonidine Tartrate affects the localization of PRKCD protein] |
CTD |
PMID:12388232 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
2-mercaptomethyl-3-guanidinoethylthiopropionic acid inhibits the reaction [[PRL co-treated with furylacryloylalanylarginine co-treated with Testosterone] results in increased abundance of Nitric Oxide]; [PRL co-treated with furylacryloylalanylarginine co-treated with Testosterone] results in increased abundance of Nitric Oxide; [PRL co-treated with furylacryloylalanylarginine] results in increased abundance of Nitric Oxide; [PRL results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:21688280 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of PTGS1 mRNA] |
CTD |
PMID:21983654 |
|
NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO |
[Ouabain results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in decreased expression of PTGS2 mRNA |
CTD |
PMID:18976649 PMID:21983654 |
|
NCBI chr 1:149,975,782...149,983,985
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of PTK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Pttg1 |
pituitary tumor-transforming gene 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of PTTG1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:43,311,071...43,318,290
Ensembl chr11:43,311,077...43,317,078
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased activity of RAF1 protein] which results in decreased secretion of Nitric Oxide |
CTD |
PMID:19039081 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Ramp1 |
receptor (calcitonin) activity modifying protein 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RAMP1 mRNA; Nitric Oxide deficiency results in increased expression of RAMP1 protein |
CTD |
PMID:16326922 |
|
NCBI chr 1:91,107,544...91,152,918
Ensembl chr 1:91,107,544...91,152,918
|
|
G |
Ramp2 |
receptor (calcitonin) activity modifying protein 2 |
multiple interactions increases expression |
ISO |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein] Nitric Oxide deficiency results in increased expression of RAMP2 mRNA; Nitric Oxide deficiency results in increased expression of RAMP2 protein |
CTD |
PMID:16326922 |
|
NCBI chr11:101,137,160...101,139,076
Ensembl chr11:101,136,854...101,150,372
|
|
G |
Ramp3 |
receptor (calcitonin) activity modifying protein 3 |
multiple interactions increases expression |
ISO |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein] Nitric Oxide deficiency results in increased expression of RAMP3 mRNA; Nitric Oxide deficiency results in increased expression of RAMP3 protein |
CTD |
PMID:16326922 |
|
NCBI chr11:6,608,507...6,627,478
Ensembl chr11:6,608,521...6,627,475
|
|
G |
Rap1a |
RAS-related protein 1a |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP1A protein] |
CTD |
PMID:16963453 |
|
NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652
|
|
G |
Rap2a |
RAS related protein 2a |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr14:120,715,873...120,744,606
Ensembl chr14:120,715,856...120,744,606
|
|
G |
Rasd1 |
RAS, dexamethasone-induced 1 |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr11:59,854,007...59,855,770
Ensembl chr11:59,854,007...59,855,770
|
|
G |
Rbbp6 |
retinoblastoma binding protein 6, ubiquitin ligase |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of RBBP6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:122,568,980...122,601,795
Ensembl chr 7:122,564,909...122,601,780
|
|
G |
Rcn1 |
reticulocalbin 1 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of RCN1 protein |
CTD |
PMID:19320461 |
|
NCBI chr 2:105,216,293...105,229,664
Ensembl chr 2:105,216,636...105,229,664
|
|
G |
Rdx |
radixin |
increases phosphorylation |
ISO |
Nitric Oxide deficiency results in increased phosphorylation of RDX protein |
CTD |
PMID:14732730 |
|
NCBI chr 9:51,958,450...52,000,038
Ensembl chr 9:51,958,473...52,011,763
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
affects localization |
ISO |
Nitric Oxide deficiency affects the localization of RELA protein |
CTD |
PMID:19631198 |
|
NCBI chr19:5,687,569...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Ren1 |
renin 1 structural |
multiple interactions increases expression |
ISO |
[Nitric Oxide deficiency co-treated with Sodium Chloride, Dietary] results in increased expression of REN protein; Nebivolol inhibits the reaction [Nitric Oxide deficiency results in increased expression of REN protein] |
CTD |
PMID:7541960 PMID:10679504 PMID:12806161 PMID:15123544 |
|
NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063
|
|
G |
Retn |
resistin |
multiple interactions increases expression |
EXP ISO |
[[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA Nitric Oxide deficiency results in increased expression of RETN mRNA |
CTD |
PMID:17063326 PMID:18369347 |
|
NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
Nitric Oxide deficiency affects the localization of and results in increased activity of RHOA protein |
CTD |
PMID:14732730 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rpl10a |
ribosomal protein L10A |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPL10A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr17:28,547,445...28,550,007
Ensembl chr17:28,547,445...28,550,007
|
|
G |
Rpl12 |
ribosomal protein L12 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:32,851,724...32,854,057
Ensembl chr 2:32,851,571...32,855,357
|
|
G |
Rpl3 |
ribosomal protein L3 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of RPL3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:79,961,982...79,967,607
Ensembl chr15:79,961,992...79,976,069
|
|
G |
Rpl8 |
ribosomal protein L8 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPL8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:76,788,271...76,790,518
Ensembl chr15:76,788,278...76,790,514
|
|
G |
Rplp0 |
ribosomal protein, large, P0 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPLP0 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:115,697,526...115,701,788
Ensembl chr 5:115,697,526...115,701,786
|
|
G |
Rplp1 |
ribosomal protein, large, P1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPLP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:61,820,565...61,821,792
Ensembl chr 9:61,820,566...61,821,824
|
|
G |
Rps12 |
ribosomal protein S12 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:23,661,081...23,663,281
Ensembl chr10:23,661,081...23,663,173
|
|
G |
Rps14 |
ribosomal protein S14 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS14 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:60,907,668...60,911,618
Ensembl chr18:60,880,170...60,911,618
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS15 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:80,128,265...80,129,948
Ensembl chr10:80,128,287...80,129,948
|
|
G |
Rps20 |
ribosomal protein S20 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS20 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:3,831,584...3,835,655
Ensembl chr 4:3,831,334...3,835,665
|
|
G |
Rps26 |
ribosomal protein S26 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS26 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:128,460,398...128,462,375
Ensembl chr10:128,460,403...128,462,616
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
multiple interactions |
ISO |
[resveratrol results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:21544240 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:28,680,846...28,685,952
Ensembl chr12:28,680,853...28,685,952
|
|
G |
Rps8 |
ribosomal protein S8 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RPS8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:117,011,033...117,013,329
Ensembl chr 4:117,011,024...117,013,440
|
|
G |
S100b |
S100 protein, beta polypeptide, neural |
multiple interactions increases secretion |
EXP ISO |
[S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; PARP1 gene mutant form inhibits the reaction [S100B protein results in increased secretion of Nitric Oxide] |
CTD |
PMID:16376947 PMID:27444121 |
|
NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993
|
|
G |
Sap30bp |
SAP30 binding protein |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of SAP30BP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:115,824,403...115,856,360
Ensembl chr11:115,824,108...115,857,551
|
|
G |
Scgb1a1 |
secretoglobin, family 1A, member 1 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of SCGB1A1 protein |
CTD |
PMID:15764486 |
|
NCBI chr19:9,061,006...9,065,320
Ensembl chr19:9,061,000...9,065,322
|
|
G |
Sdc2 |
syndecan 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of SDC2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of SELE protein]] |
CTD |
PMID:14762100 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Setdb2 |
SET domain, bifurcated 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of SETDB2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr14:59,639,458...59,678,329
Ensembl chr14:59,639,458...59,678,333
|
|
G |
Sftpa1 |
surfactant associated protein A1 |
multiple interactions decreases expression |
ISO |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPA1 mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPA1 mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr14:40,853,745...40,858,330
Ensembl chr14:40,853,739...40,858,409
|
|
G |
Sftpb |
surfactant associated protein B |
multiple interactions decreases expression |
ISO |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPB mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPB mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr 6:72,281,594...72,291,356
Ensembl chr 6:72,281,594...72,291,354
|
|
G |
Sftpc |
surfactant associated protein C |
multiple interactions decreases expression |
ISO |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPC mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPC mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr14:70,758,381...70,761,521
Ensembl chr14:70,758,389...70,761,521
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
SIRT1 protein affects the reaction [INS protein results in increased secretion of Nitric Oxide]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]] |
CTD |
PMID:20960276 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc11a2 |
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 |
multiple interactions affects expression |
ISO EXP |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] Nitric Oxide affects the expression of SLC11A2 protein alternative form |
CTD |
PMID:16232120 PMID:16908409 |
|
NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953
|
|
G |
Slc40a1 |
solute carrier family 40 (iron-regulated transporter), member 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of SLC40A1 protein |
CTD |
PMID:24184442 |
|
NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683
|
|
G |
Slc4a2 |
solute carrier family 4 (anion exchanger), member 2 |
multiple interactions |
ISO |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]] |
CTD |
PMID:12612912 |
|
NCBI chr 5:24,628,939...24,645,945
Ensembl chr 5:24,628,835...24,645,948
|
|
G |
Slc5a2 |
solute carrier family 5 (sodium/glucose cotransporter), member 2 |
decreases activity |
ISO |
Nitric Oxide deficiency results in decreased activity of SLC5A2 protein |
CTD |
PMID:17940347 |
|
NCBI chr 7:127,864,855...127,871,602
Ensembl chr 7:127,864,829...127,871,602
|
|
G |
Slc7a7 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 |
decreases abundance |
ISO |
SLC7A7 protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:11544277 |
|
NCBI chr14:54,606,899...54,657,525
Ensembl chr14:54,606,899...54,655,237
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[SMAD4 protein co-treated with SMAD3 protein] affects the susceptibility to Nitric Oxide; Nitric Oxide results in increased activity of [SMAD4 protein binds to SMAD3 protein] |
CTD |
PMID:15949472 |
|
NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276
|
|
G |
Smad4 |
SMAD family member 4 |
multiple interactions |
ISO |
[SMAD4 protein co-treated with SMAD3 protein] affects the susceptibility to Nitric Oxide; Nitric Oxide results in increased activity of [SMAD4 protein binds to SMAD3 protein] |
CTD |
PMID:15949472 |
|
NCBI chr18:73,767,861...73,836,862
Ensembl chr18:73,772,080...73,836,851
|
|
G |
Snca |
synuclein, alpha |
multiple interactions |
ISO |
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:24290359 |
|
NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
|
|
G |
Snta1 |
syntrophin, acidic 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of SNTA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:154,218,234...154,250,004
Ensembl chr 2:154,218,233...154,250,019
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
increases abundance multiple interactions decreases response to substance |
EXP ISO |
SOD1 protein results in increased abundance of Nitric Oxide Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of SOD1 mRNA] SOD1 protein inhibits the reaction [[spermine nitric oxide complex results in increased abundance of Nitric Oxide] which results in increased abundance of Superoxides]; SOD1 protein inhibits the reaction [Nitric Oxide results in decreased activity of NOS3 protein]; SOD1 protein inhibits the reaction [Nitric Oxide results in increased abundance of Peroxynitrous Acid] Nitric Oxide deficiency results in decreased susceptibility to SOD1 protein mutant form |
CTD |
PMID:12489993 PMID:19845829 PMID:21443684 PMID:21983654 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases expression decreases abundance affects abundance multiple interactions |
ISO |
Nitric Oxide deficiency results in increased expression of SOD2 protein SOD2 protein results in decreased abundance of Nitric Oxide SOD2 protein affects the abundance of Nitric Oxide [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein]; 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA]; [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA; Dactinomycin inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of SOD2 mRNA]; SOD2 protein inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of SOD2 protein] |
CTD |
PMID:9576743 PMID:14996425 PMID:15925750 PMID:19320461 PMID:20110409 PMID:21983654 PMID:23964924 More...
|
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of SPP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18296501 |
|
NCBI chr 2:157,265,790...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
STAT1 protein promotes the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:23106696 |
|
NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
decreases expression multiple interactions |
EXP |
Nitric Oxide results in decreased expression of STAT5A protein STAT5A protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] |
CTD |
PMID:16886906 |
|
NCBI chr11:100,750,177...100,775,995
Ensembl chr11:100,750,177...100,775,995
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
multiple interactions decreases expression |
EXP |
STAT5B protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] Nitric Oxide results in decreased expression of STAT5B protein |
CTD |
PMID:16886906 |
|
NCBI chr11:100,671,557...100,741,407
Ensembl chr11:100,671,557...100,741,550
|
|
G |
Suv39h2 |
suppressor of variegation 3-9 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of SUV39H2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 2:3,456,852...3,476,085
Ensembl chr 2:3,456,852...3,476,068
|
|
G |
Syn1 |
synapsin I |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of SYN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:20,726,750...20,787,157
Ensembl chr X:20,726,750...20,787,243
|
|
G |
Taldo1 |
transaldolase 1 |
multiple interactions decreases abundance |
EXP |
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of Nitric Oxide] |
CTD |
PMID:19436114 |
|
NCBI chr 7:140,972,073...140,982,889
Ensembl chr 7:140,972,112...140,982,881
|
|
G |
Tbca |
tubulin cofactor A |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of TBCA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr13:94,925,428...94,979,431
Ensembl chr13:94,925,418...94,979,430
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions decreases expression |
ISO |
[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC Nitric Oxide deficiency results in decreased expression of TFRC protein |
CTD |
PMID:24184442 PMID:24964743 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
candesartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of TGFB1 mRNA]; Nitric Oxide inhibits the reaction [Paraquat results in increased expression of TGFB1 protein] |
CTD |
PMID:15820443 PMID:16778335 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Thbd |
thrombomodulin |
multiple interactions decreases expression |
ISO |
candesartan inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]; Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein] |
CTD |
PMID:16778335 |
|
NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108
|
|
G |
Timp2 |
tissue inhibitor of metalloproteinase 2 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of TIMP2 mRNA; Nitric Oxide results in decreased expression of TIMP2 protein |
CTD |
PMID:18796497 |
|
NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566
|
|
G |
Tinf2 |
Terf1 (TRF1)-interacting nuclear factor 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of TINF2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr14:55,913,664...55,919,301
Ensembl chr14:55,912,146...55,919,277
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression multiple interactions |
ISO EXP |
Nitric Oxide deficiency results in decreased expression of TJP1 protein [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased expression of TJP1 mRNA |
CTD |
PMID:15763998 PMID:25870319 |
|
NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529
|
|
G |
Tk1 |
thymidine kinase 1 |
increases mutagenesis |
ISO |
Nitric Oxide results in increased mutagenesis of TK1 gene |
CTD |
PMID:22303861 PMID:28454271 |
|
NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918
|
|
G |
Tle5 |
TLE family member 5, transcriptional modulator |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of TLE5 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:81,395,278...81,402,205
Ensembl chr10:81,395,322...81,402,196
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
TLR4 gene mutant form inhibits the reaction [Fungal Polysaccharides results in increased abundance of Nitric Oxide]; TLR4 protein affects the reaction [Plant Extracts results in increased chemical synthesis of Nitric Oxide]; TLR4 protein affects the reaction [Polysaccharides results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:22687552 PMID:23246459 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases expression increases metabolic processing decreases abundance increases secretion |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]; Alginic Acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; allicin inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Ascorbic Acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Dactinomycin inhibits the reaction [TNF results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; martentoxin, Buthus martensi inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; N,N-diacetylcystine inhibits the reaction [TNF protein results in decreased abundance of Nitric Oxide]; pyrrolidine dithiocarbamic acid promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]; Wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Dexamethasone inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Estriol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Guanidines analog inhibits the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; pimagedine inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of TNF protein] which results in increased chemical synthesis of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Y 27632 promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in increased expression of TNF protein; Nitric Oxide results in increased expression of TNF protein TNF protein results in increased metabolism of Nitric Oxide 7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Nitric Oxide deficiency results in increased expression of TNF protein]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; KMUP 1 inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Polyphenols inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; S-methylisothiopseudouronium inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; TNF protein affects the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; Vitamin E inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide]; zaprinast inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide] TNF protein results in increased abundance of Nitric Oxide; TNF results in increased abundance of Nitric Oxide Nitric Oxide results in increased secretion of TNF protein; TNF protein results in increased secretion of Nitric Oxide |
CTD |
PMID:7519435 PMID:8341679 PMID:8903404 PMID:8975779 PMID:9388267 PMID:10706834 PMID:10909967 PMID:11063824 PMID:11282106 PMID:12612912 PMID:12723939 PMID:13678430 PMID:14617770 PMID:14623498 PMID:15223066 PMID:15451797 PMID:15485488 PMID:16168523 PMID:16366677 PMID:16492401 PMID:16754782 PMID:16968468 PMID:17026986 PMID:17067557 PMID:17157857 PMID:17729120 PMID:18206661 PMID:18207479 PMID:18369347 PMID:19393675 PMID:20626112 PMID:20708382 PMID:21943492 PMID:23439570 PMID:24086172 PMID:25766886 PMID:32613688 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases phosphorylation decreases expression affects response to substance increases glutathionylation increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; Caffeine inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein]; wortmannin inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of TRP53 mRNA Nitric Oxide results in decreased expression of TRP53 protein [7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat results in increased phosphorylation of TP53 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein TP53 protein affects the susceptibility to Nitric Oxide Nitric Oxide results in increased glutathionylation of TP53 protein Nitric Oxide results in increased expression of TP53 protein |
CTD |
PMID:7673702 PMID:8982730 PMID:9743513 PMID:10608825 PMID:14634119 PMID:15177039 PMID:15979383 PMID:16024610 PMID:17555331 PMID:20478973 More...
|
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trp53bp1 |
transformation related protein 53 binding protein 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of TRP53BP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:121,025,316...121,126,830
Ensembl chr 2:121,023,762...121,101,888
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of TXNDC5 protein |
CTD |
PMID:19320461 |
|
NCBI chr13:38,684,242...38,712,800
Ensembl chr13:38,684,055...38,712,800
|
|
G |
Ubc |
ubiquitin C |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of UBC mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of UBE2L3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr16:16,969,879...17,019,376
Ensembl chr16:16,969,877...17,020,513
|
|
G |
Ucn |
urocortin |
increases abundance |
ISO |
UCN protein results in increased abundance of Nitric Oxide |
CTD |
PMID:20237592 |
|
NCBI chr 5:31,295,333...31,296,239
Ensembl chr 5:31,295,407...31,296,173
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression increases secretion |
ISO |
Nitric Oxide deficiency results in decreased expression of VEGFA mRNA VEGFA protein results in increased secretion of Nitric Oxide |
CTD |
PMID:15249212 PMID:16733097 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
ISO |
Nitric Oxide results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
XDH protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide] |
CTD |
PMID:20888885 |
|
NCBI chr17:74,190,890...74,257,369
Ensembl chr17:74,190,890...74,257,191
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression increases expression |
ISO EXP |
Nitric Oxide results in decreased expression of XIAP mRNA Nitric Oxide results in increased expression of XIAP protein |
CTD |
PMID:14634119 PMID:15126337 |
|
NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533
|
|
G |
Zfp422 |
zinc finger protein 422 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of ZFP422 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:116,600,977...116,605,960
Ensembl chr 6:116,600,977...116,605,960
|
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
multiple interactions |
EXP |
ABCC1 protein affects the reaction [AGT protein results in increased abundance of Superoxides] |
CTD |
PMID:17272743 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Aco1 |
aconitase 1 |
decreases activity multiple interactions |
EXP |
Superoxides results in decreased activity of ACO1 protein [SOD1 protein results in decreased abundance of Superoxides] which results in increased expression of ACO1 protein |
CTD |
PMID:28542246 |
|
NCBI chr 4:40,143,265...40,199,009
Ensembl chr 4:40,143,081...40,198,338
|
|
G |
Aco2 |
aconitase 2, mitochondrial |
multiple interactions decreases activity |
ISO |
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron |
CTD |
PMID:16162655 |
|
NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
ISO |
ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] |
CTD |
PMID:10947063 |
|
NCBI chr 2:163,568,491...163,592,161
Ensembl chr 2:163,568,504...163,592,159
|
|
G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
multiple interactions increases abundance |
EXP ISO |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; ABCC1 protein affects the reaction [AGT protein results in increased abundance of Superoxides]; acetovanillone inhibits the reaction [AGT protein results in increased abundance of Superoxides]; ATOX1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; NOS3 protein affects the reaction [AGT protein results in increased abundance of Superoxides]; Propranolol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; SOD1 protein inhibits the reaction [AGT protein results in increased abundance of Superoxides]; SOD3 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; acetovanillone inhibits the reaction [AGT protein results in increased abundance of Superoxides]; bisindolylmaleimide I inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]] AGT protein modified form results in increased abundance of Superoxides; AGT protein results in increased abundance of Superoxides SOD1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:12606818 PMID:16531806 PMID:16864745 PMID:17272743 PMID:17391658 PMID:18250367 PMID:18768397 PMID:20881940 PMID:22753205 PMID:24363997 More...
|
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
[Mevinphos results in increased activity of AGTR1A protein] promotes the reaction [NOX1 protein results in increased abundance of Superoxides] |
CTD |
PMID:23824088 |
|
NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
multiple interactions |
ISO |
[AKR1C3 protein results in increased reduction of 9,10-phenanthrenequinone] which results in increased abundance of Superoxides; [AKR1C3 protein results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:19442656 PMID:21910479 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr7a5 |
aldo-keto reductase family 7, member A5 (aflatoxin aldehyde reductase) |
multiple interactions |
ISO |
[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:21910479 |
|
NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
|
|
G |
Alb |
albumin |
increases chemical synthesis multiple interactions |
ISO |
ALB protein modified form results in increased chemical synthesis of Superoxides Etomidate promotes the reaction [ALB protein modified form results in increased chemical synthesis of Superoxides] |
CTD |
PMID:25421967 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Aldh5a1 |
aldhehyde dehydrogenase family 5, subfamily A1 |
multiple interactions |
EXP |
[ALDH5A1 gene mutant form results in increased susceptibility to 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] which results in increased abundance of Superoxides; [ALDH5A1 gene mutant form results in increased susceptibility to NCS 382] which results in increased abundance of Superoxides |
CTD |
PMID:29031482 |
|
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
|
|
G |
Apoe |
apolipoprotein E |
increases chemical synthesis increases abundance multiple interactions |
EXP |
APOE gene mutant form results in increased chemical synthesis of Superoxides APOE gene mutant form results in increased abundance of Superoxides imisopasem manganese inhibits the reaction [APOE gene mutant form results in increased chemical synthesis of Superoxides]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [APOE gene mutant form results in increased abundance of Superoxides] |
CTD |
PMID:11397713 PMID:12871831 |
|
NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113
|
|
G |
App |
amyloid beta (A4) precursor protein |
multiple interactions increases chemical synthesis |
ISO |
3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine inhibits the reaction [APP gene mutant form results in increased chemical synthesis of Superoxides]; GW 501516 inhibits the reaction [APP gene mutant form results in increased chemical synthesis of Superoxides]; resveratrol inhibits the reaction [APP protein results in increased abundance of Superoxides] |
CTD |
PMID:16212921 PMID:22886847 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Superoxides promotes the reaction [methylselenic acid results in decreased expression of AR protein] |
CTD |
PMID:16928829 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
multiple interactions |
ISO |
1-Butanol inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 1-Butanol inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]; ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] |
CTD |
PMID:10931844 |
|
NCBI chr12:69,418,924...69,422,754
Ensembl chr12:69,418,924...69,420,557
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects abundance |
EXP |
ARRB2 protein affects the abundance of Superoxides |
CTD |
PMID:16210646 |
|
NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
EXP |
ATOX1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:22753205 |
|
NCBI chr11:55,337,463...55,352,034
Ensembl chr11:55,337,467...55,352,065
|
|
G |
Atp7a |
ATPase, Cu++ transporting, alpha polypeptide |
increases abundance multiple interactions |
EXP |
ATP7A mutant form results in increased abundance of Superoxides [ATP7A protein results in increased activity of SOD3 protein] which results in decreased chemical synthesis of Superoxides; ATP7A gene mutant form promotes the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]; ATP7A protein inhibits the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] |
CTD |
PMID:18768397 PMID:23884884 |
|
NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein]; CAT protein inhibits the reaction [Superoxides results in increased secretion of TGFB1 protein] |
CTD |
PMID:19268487 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cbs |
cystathionine beta-synthase |
affects abundance multiple interactions |
EXP |
CBS protein affects the abundance of Superoxides SMPD1 protein affects the reaction [CBS protein affects the abundance of Superoxides] |
CTD |
PMID:23024785 |
|
NCBI chr17:31,831,597...31,856,207
Ensembl chr17:31,827,868...31,856,212
|
|
G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
multiple interactions increases expression |
ISO EXP |
Superoxides affects the reaction [Fructose results in increased secretion of CCL2 protein] Superoxides results in increased expression of CCL2 mRNA 1,3-dimethylthiourea inhibits the reaction [Superoxides results in increased expression of CCL2 mRNA] |
CTD |
PMID:8856246 PMID:19158351 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Cd38 |
CD38 antigen |
affects localization multiple interactions |
EXP |
Superoxides affects the localization of CD38 protein tempol inhibits the reaction [Superoxides affects the localization of CD38 protein] |
CTD |
PMID:23940720 |
|
NCBI chr 5:44,026,151...44,069,716
Ensembl chr 5:44,025,895...44,069,717
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions |
ISO |
CRP protein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Superoxides] |
CTD |
PMID:9767445 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
multiple interactions increases abundance |
ISO |
CYBA protein promotes the reaction [arsenite results in increased abundance of Superoxides] CYBA protein results in increased abundance of Superoxides |
CTD |
PMID:10720412 PMID:14871555 PMID:20523355 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
EXP ISO |
CYBB mutant form inhibits the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB protein affects the reaction [Folic Acid deficiency results in increased chemical synthesis of Superoxides]; CYBB protein affects the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] IL1B protein promotes the reaction [CYBB protein results in increased chemical synthesis of Superoxides] |
CTD |
PMID:16354686 PMID:17275678 PMID:20116427 PMID:21647593 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases abundance |
EXP |
CYP1A1 protein results in increased abundance of Superoxides |
CTD |
PMID:20634294 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Dcxr |
dicarbonyl L-xylulose reductase |
multiple interactions increases chemical synthesis |
ISO |
[DCXR protein results in increased metabolism of Vitamin K 3] which results in increased chemical synthesis of Superoxides; Diacetyl inhibits the reaction [[DCXR protein results in increased metabolism of Vitamin K 3] which results in increased chemical synthesis of Superoxides] DCXR protein results in increased chemical synthesis of Superoxides |
CTD |
PMID:28595002 |
|
NCBI chr11:120,615,372...120,618,110
Ensembl chr11:120,616,225...120,618,107
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases abundance increases expression multiple interactions |
EXP |
DDIT3 protein results in increased abundance of Superoxides Superoxides results in increased expression of DDIT3 mRNA; Superoxides results in increased expression of DDIT3 protein [DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGA3 protein; [DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGB1 protein |
CTD |
PMID:16400006 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
ISO EXP |
[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides; Catechin inhibits the reaction [EDN1 protein results in increased abundance of Superoxides]; NOS3 protein affects the reaction [[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides]; Polyphenols inhibits the reaction [[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides] NOX1 mutant form inhibits the reaction [EDN1 protein results in increased abundance of Superoxides] |
CTD |
PMID:20977430 PMID:23940720 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Ednra |
endothelin receptor type A |
affects abundance |
ISO |
EDNRA protein affects the abundance of Superoxides |
CTD |
PMID:12600921 |
|
NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases abundance |
ISO |
EP300 protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr15:81,470,329...81,536,278
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides] |
CTD |
PMID:25490417 |
|
NCBI chr 5:137,481,282...137,484,078
Ensembl chr 5:137,481,282...137,531,504
|
|
G |
Ercc6 |
excision repair cross-complementing rodent repair deficiency, complementation group 6 |
multiple interactions decreases abundance increases abundance |
ISO |
3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides] ERCC6 protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
[4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol binds to and results in increased activity of ESR1 protein] which results in decreased abundance of Superoxides; [ESR1 protein results in increased susceptibility to Estradiol] which results in increased abundance of Superoxides; ESR1 protein affects the reaction [Estradiol results in decreased chemical synthesis of Superoxides] |
CTD |
PMID:18354059 PMID:23000059 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions increases abundance |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides] |
CTD |
PMID:27385396 |
|
NCBI chr X:67,722,142...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Superoxides affects the reaction [Glucose results in increased expression of FN1 mRNA] |
CTD |
PMID:16572112 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions increases expression |
EXP |
SOD2 protein inhibits the reaction [Superoxides results in increased expression of FOS mRNA] |
CTD |
PMID:9067545 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
UCP1 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] SOD2 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] |
CTD |
PMID:11050244 |
|
NCBI chr 6:125,138,815...125,143,430
Ensembl chr 6:125,138,678...125,143,430
|
|
G |
Gas5 |
growth arrest specific 5 |
increases expression |
EXP |
Superoxides results in increased expression of GAS5 mRNA; Superoxides results in increased expression of GAS5 protein |
CTD |
PMID:16400006 |
|
NCBI chr 1:160,862,171...160,866,109
Ensembl chr 1:160,861,992...160,866,116
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
affects abundance |
EXP |
GCH1 protein affects the abundance of Superoxides |
CTD |
PMID:21963838 |
|
NCBI chr14:47,391,352...47,426,870
Ensembl chr14:47,391,352...47,426,870
|
|
G |
Hc |
hemolytic complement |
multiple interactions increases abundance |
ISO |
8-(4-sulfophenyl)theophylline promotes the reaction [C5 protein modified form results in increased abundance of Superoxides]; Theophylline inhibits the reaction [C5 protein modified form results in increased abundance of Superoxides]; Theophylline promotes the reaction [C5 protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:10947063 |
|
NCBI chr 2:34,873,341...34,958,518
Ensembl chr 2:34,873,343...34,951,450
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases abundance decreases abundance |
EXP ISO |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased abundance of Superoxides; [cobaltous chloride results in increased expression of HMOX1 protein] which results in decreased abundance of Superoxides; [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Superoxides; [tin mesoporphyrin results in decreased activity of HMOX1 protein] which results in increased abundance of Superoxides; Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides] [tetrathiomolybdate analog results in increased abundance of Superoxides] which results in increased reduction of HMOX1 protein HMOX1 protein results in decreased abundance of Superoxides |
CTD |
PMID:15821039 PMID:16959961 PMID:18073186 PMID:18178725 PMID:18334666 PMID:19323979 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
increases abundance multiple interactions |
ISO |
HRAS protein mutant form results in increased abundance of Superoxides [HRAS protein mutant form results in increased abundance of Superoxides] which results in decreased susceptibility to TNF protein |
CTD |
PMID:11313892 |
|
NCBI chr 7:140,769,847...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Hspb1 |
heat shock protein 1 |
multiple interactions decreases abundance |
EXP |
[tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex results in decreased abundance of Superoxides] which results in decreased expression of HSPB1 protein HSPB1 protein results in decreased abundance of Superoxides |
CTD |
PMID:14975446 PMID:19193722 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Ier3 |
immediate early response 3 |
affects chemical synthesis |
EXP |
IER3 protein affects the chemical synthesis of Superoxides |
CTD |
PMID:20713914 |
|
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases abundance |
ISO |
IGF1 protein results in decreased abundance of Superoxides |
CTD |
PMID:22843358 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
diphenyleneiodonium inhibits the reaction [IL1B protein results in increased abundance of Superoxides]; IL1B protein promotes the reaction [CYBB protein results in increased chemical synthesis of Superoxides] |
CTD |
PMID:16354686 PMID:21211511 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]; Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]; ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] |
CTD |
PMID:16238794 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Itga3 |
integrin alpha 3 |
multiple interactions |
EXP |
[DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGA3 protein |
CTD |
PMID:16400006 |
|
NCBI chr11:94,935,301...94,967,637
Ensembl chr11:94,935,300...94,967,627
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
EXP |
[DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGB1 protein |
CTD |
PMID:16400006 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions increases expression |
ISO EXP |
Superoxides affects the reaction [Glucose results in increased phosphorylation of JUN protein] Superoxides results in increased expression of JUN mRNA SOD2 protein inhibits the reaction [Superoxides results in increased expression of JUN mRNA] |
CTD |
PMID:9067545 PMID:16572112 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kat2a |
K(lysine) acetyltransferase 2A |
decreases abundance |
ISO |
KAT2A protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr11:100,595,572...100,604,427
Ensembl chr11:100,595,572...100,603,291
|
|
G |
Kat2b |
K(lysine) acetyltransferase 2B |
decreases abundance |
ISO |
KAT2B protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr17:53,873,802...53,979,749
Ensembl chr17:53,873,889...53,979,748
|
|
G |
Kdr |
kinase insert domain protein receptor |
increases phosphorylation |
ISO |
Superoxides results in increased phosphorylation of KDR protein |
CTD |
PMID:19571580 |
|
NCBI chr 5:76,093,487...76,139,885
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
EXP ISO |
acetovanillone inhibits the reaction [LEP protein results in increased abundance of Superoxides]; BQ 788 inhibits the reaction [LEP protein results in increased abundance of Superoxides]; cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [LEP protein results in increased abundance of Superoxides] [LEP protein results in increased oxidation of Fatty Acids] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:11342529 PMID:16380530 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lepr |
leptin receptor |
multiple interactions increases abundance |
EXP |
acetovanillone inhibits the reaction [LEPR gene mutant form results in increased abundance of Superoxides]; resveratrol inhibits the reaction [LEPR gene mutant form results in increased abundance of Superoxides] |
CTD |
PMID:19478208 |
|
NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK1 protein] Superoxides results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16572112 PMID:19268487 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK3 protein] Superoxides results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16572112 PMID:19268487 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
Superoxides results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:33290831 |
|
NCBI chr14:33,099,855...33,169,215
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
EXP |
Superoxides results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:33290831 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[MPO protein results in increased oxidation of hydrazine] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:26867495 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
ISO |
MT3 protein results in decreased susceptibility to Superoxides |
CTD |
PMID:12383939 |
|
NCBI chr 8:94,879,235...94,880,776
Ensembl chr 8:94,879,235...94,880,774
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
NCF1 protein affects the reaction [Lipopolysaccharides results in increased abundance of Superoxides] |
CTD |
PMID:17448908 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
NCF2 protein affects the reaction [Lipopolysaccharides results in increased abundance of Superoxides] |
CTD |
PMID:17448908 |
|
NCBI chr 1:152,675,904...152,712,741
Ensembl chr 1:152,675,945...152,712,742
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
[Ozone results in increased expression of NOS2 protein] which results in increased abundance of Superoxides |
CTD |
PMID:11919077 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
multiple interactions affects chemical synthesis decreases abundance increases abundance |
ISO EXP |
7,8-dihydrobiopterin promotes the reaction [NOS3 protein results in increased abundance of Superoxides]; [Equol results in increased chemical synthesis of Superoxides] which results in increased activity of and results in increased phosphorylation of NOS3 protein; sapropterin deficiency inhibits the reaction [NOS3 protein results in increased abundance of Superoxides]; sapropterin deficiency promotes the reaction [NOS3 protein results in increased abundance of Superoxides]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Equol results in increased chemical synthesis of Superoxides] which results in increased phosphorylation of NOS3 protein] NOS3 protein affects the chemical synthesis of Superoxides NOS3 protein results in decreased abundance of Superoxides [NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides; EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides]; NOS3 protein affects the reaction [AGT protein results in increased abundance of Superoxides] [Calcimycin results in increased activity of NOS3 protein] which results in increased abundance of Superoxides; Nitroglycerin promotes the reaction [[Calcimycin results in increased activity of NOS3 protein] which results in increased abundance of Superoxides]; NOS3 protein affects the reaction [[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides] |
CTD |
PMID:10625313 PMID:17272743 PMID:18714161 PMID:19011239 PMID:19696404 PMID:20977430 PMID:21300668 PMID:25490417 More...
|
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions increases abundance |
ISO EXP |
[Mevinphos results in increased activity of AGTR1A protein] promotes the reaction [NOX1 protein results in increased abundance of Superoxides]; NOX1 mRNA promotes the reaction [Tobacco Smoke Pollution results in increased chemical synthesis of Superoxides] diphenyleneiodonium inhibits the reaction [NOX1 protein results in increased abundance of Superoxides]; NOX1 mutant form inhibits the reaction [EDN1 protein results in increased abundance of Superoxides] |
CTD |
PMID:23824088 PMID:23940720 PMID:24912985 PMID:27816504 |
|
NCBI chr X:132,987,170...133,038,455
Ensembl chr X:132,987,170...133,122,705
|
|
G |
Nox3 |
NADPH oxidase 3 |
multiple interactions |
EXP |
[resveratrol results in decreased expression of and results in decreased activity of NOX3 protein] which results in decreased abundance of Superoxides |
CTD |
PMID:20675566 |
|
NCBI chr17:3,685,515...3,746,536
Ensembl chr17:3,685,515...3,746,536
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
NOX4 promotes the reaction [sodium arsenite results in increased abundance of Superoxides] |
CTD |
PMID:26535918 |
|
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
|
|
G |
Park7 |
Parkinson disease (autosomal recessive, early onset) 7 |
multiple interactions |
EXP |
PARK7 protein affects the reaction [Paraquat results in increased abundance of Superoxides] |
CTD |
PMID:21300143 |
|
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 alpha 1 |
affects abundance |
ISO |
PDHA1 protein affects the abundance of Superoxides |
CTD |
PMID:21846590 |
|
NCBI chr X:158,905,215...158,921,426
Ensembl chr X:158,905,205...158,921,409
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
affects abundance |
EXP |
PINK1 protein affects the abundance of Superoxides |
CTD |
PMID:21421046 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Polg |
polymerase (DNA directed), gamma |
multiple interactions increases chemical synthesis |
EXP |
Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin inhibits the reaction [POLG protein results in increased chemical synthesis of Superoxides]; polyethylene glycol-superoxide dismutase inhibits the reaction [POLG gene mutant form results in increased chemical synthesis of Superoxides]; Rotenone promotes the reaction [POLG gene mutant form results in increased chemical synthesis of Superoxides] |
CTD |
PMID:30038268 |
|
NCBI chr 7:79,095,979...79,117,659
Ensembl chr 7:79,095,979...79,116,110
|
|
G |
Pomc |
pro-opiomelanocortin-alpha |
increases abundance |
ISO |
POMC protein results in increased abundance of Superoxides |
CTD |
PMID:16620303 |
|
NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642
|
|
G |
Pon2 |
paraoxonase 2 |
increases expression |
EXP |
Superoxides results in increased expression of PON2 protein |
CTD |
PMID:15544923 |
|
NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO EXP |
[POR protein results in increased metabolism of Diquat] which results in increased abundance of Superoxides; [POR protein results in increased metabolism of Paraquat] which results in increased abundance of Superoxides; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased abundance of Superoxides] [POR protein results in increased metabolism of Diquat] which results in increased abundance of Superoxides; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Superoxides] |
CTD |
PMID:21215309 |
|
NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[Ethanol results in increased localization of and results in increased activity of PRKCA protein] promotes the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Superoxides] |
CTD |
PMID:10651808 |
|
NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
[Ethanol results in increased localization of and results in increased activity of PRKCB protein] promotes the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Superoxides] |
CTD |
PMID:10651808 |
|
NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
resveratrol inhibits the reaction [Superoxides results in increased expression of PTGS2 protein] |
CTD |
PMID:10718345 |
|
NCBI chr 1:149,975,782...149,983,985
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
multiple interactions |
ISO |
[resveratrol results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides |
CTD |
PMID:21544240 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Selenoh |
selenoprotein H |
decreases abundance |
ISO |
SELENOH protein results in decreased abundance of Superoxides |
CTD |
PMID:17389926 |
|
NCBI chr 2:84,499,559...84,501,052
Ensembl chr 2:84,499,559...84,501,114
|
|
G |
Serpine1 |
serine (or cysteine) peptidase inhibitor, clade E, member 1 |
multiple interactions |
ISO |
[[Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein] which results in decreased secretion of SERPINE1 protein |
CTD |
PMID:11681624 |
|
NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [Tobacco Smoke Pollution results in increased abundance of Superoxides]] |
CTD |
PMID:18424637 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc25a14 |
solute carrier family 25 (mitochondrial carrier, brain), member 14 |
multiple interactions |
ISO |
SLC25A14 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased abundance of Superoxides]; SLC25A14 protein inhibits the reaction [Dopamine results in increased abundance of Superoxides] |
CTD |
PMID:20600837 |
|
NCBI chr X:47,712,295...47,751,175
Ensembl chr X:47,712,290...47,751,171
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1, acid lysosomal |
multiple interactions |
EXP |
SMPD1 protein affects the reaction [CBS protein affects the abundance of Superoxides] |
CTD |
PMID:23024785 |
|
NCBI chr 7:105,203,567...105,207,596
Ensembl chr 7:105,203,567...105,207,596
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
increases abundance decreases abundance multiple interactions decreases chemical synthesis |
EXP ISO |
SOD1 protein results in increased abundance of Superoxides SOD1 protein results in decreased abundance of Superoxides [[Chelating Agents binds to Copper] which affects the activity of SOD1 protein] which results in increased abundance of Superoxides; [tetrathiomolybdate results in decreased activity of SOD1 protein] which results in increased abundance of Superoxides; SOD1 protein inhibits the reaction [[spermine nitric oxide complex results in increased abundance of Nitric Oxide] which results in increased abundance of Superoxides]; SOD1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] SOD1 protein results in decreased chemical synthesis of Superoxides [SOD1 protein results in decreased abundance of Superoxides] which results in increased expression of ACO1 protein; SOD1 protein inhibits the reaction [AGT protein results in increased abundance of Superoxides] |
CTD |
PMID:11756504 PMID:12489993 PMID:15364863 PMID:15829915 PMID:17391658 PMID:18480265 PMID:21443684 PMID:21900685 PMID:24363997 PMID:28542246 PMID:31162603 More...
|
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
increases metabolic processing affects metabolic processing decreases abundance multiple interactions increases expression affects abundance affects chemical synthesis |
ISO EXP |
SOD2 protein results in increased metabolism of Superoxides SOD2 protein polymorphism affects the metabolism of Superoxides SOD2 protein results in decreased abundance of Superoxides [tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex results in decreased abundance of Superoxides] which results in decreased expression of SOD2 protein; SOD2 protein affects the reaction [Troglitazone results in increased abundance of Superoxides]; SOD2 protein inhibits the reaction [sodium arsenite results in increased abundance of Superoxides]; SOD2 protein inhibits the reaction [Superoxides results in increased expression of FOS mRNA]; SOD2 protein inhibits the reaction [Superoxides results in increased expression of JUN mRNA] Superoxides results in increased expression of SOD2 protein [Rotenone results in increased abundance of Superoxides] which results in increased expression of SOD2 protein; [TNF protein results in increased expression of SOD2 protein] which results in decreased susceptibility to Superoxides; SOD2 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] [SOD2 protein results in increased metabolism of Superoxides] which results in increased chemical synthesis of Hydrogen Peroxide; Tamoxifen inhibits the reaction [SOD2 protein affects the abundance of Superoxides] SOD2 protein affects the chemical synthesis of Superoxides |
CTD |
PMID:1850207 PMID:9067545 PMID:11050244 PMID:16179351 PMID:17150972 PMID:17901229 PMID:18594523 PMID:19193722 PMID:19265433 PMID:20304815 PMID:20638473 PMID:25561743 PMID:26108578 PMID:28495429 PMID:32243540 More...
|
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sod3 |
superoxide dismutase 3, extracellular |
multiple interactions |
EXP |
[ATP7A protein results in increased activity of SOD3 protein] which results in decreased chemical synthesis of Superoxides; [Streptozocin results in decreased activity of SOD3 protein] which results in increased chemical synthesis of Superoxides; SOD3 gene mutant form promotes the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; SOD3 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:16864745 PMID:23884884 |
|
NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases secretion increases abundance |
ISO EXP |
Superoxides affects the reaction [Glucose results in increased expression of TGFB1 mRNA] Superoxides results in increased secretion of TGFB1 protein [[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein; CAT protein inhibits the reaction [[[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein]; CAT protein inhibits the reaction [Superoxides results in increased secretion of TGFB1 protein] TGFB1 protein results in increased abundance of Superoxides |
CTD |
PMID:12606818 PMID:16572112 PMID:19268487 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects abundance decreases abundance increases abundance |
ISO EXP |
[HRAS protein mutant form results in increased abundance of Superoxides] which results in decreased susceptibility to TNF protein; [N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides; [TNF protein results in increased expression of SOD2 protein] which results in decreased susceptibility to Superoxides; acetovanillone inhibits the reaction [TNF protein results in increased abundance of Superoxides]; Acetylcysteine inhibits the reaction [TNF protein results in increased abundance of Superoxides]; cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased abundance of Superoxides]; Cyclosporine inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [TNF protein results in increased abundance of Superoxides]; Tacrolimus inhibits the reaction [[N-Formylmethionine Leucyl-Phenylalanine co-treated with TNF protein] results in increased abundance of Superoxides] TNF protein affects the abundance of Superoxides TNF gene mutant form results in decreased abundance of Superoxides TNF protein inhibits the reaction [Dichloroacetic Acid results in increased abundance of Superoxides] |
CTD |
PMID:1850207 PMID:11121130 PMID:11313892 PMID:15450858 PMID:19478208 PMID:19608869 PMID:21211511 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] |
CTD |
PMID:20457604 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] |
CTD |
PMID:20457604 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Ucp1 |
uncoupling protein 1 (mitochondrial, proton carrier) |
multiple interactions |
ISO |
UCP1 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] |
CTD |
PMID:11050244 |
|
NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
multiple interactions decreases abundance |
ISO |
[[benzo(a)pyrene-1,6-quinone results in increased abundance of Superoxides] co-treated with [benzo(a)pyrene-1,6-quinone results in decreased abundance of Hydrogen Peroxide]] results in increased expression of UCP2 mRNA UCP2 protein results in decreased abundance of Superoxides |
CTD |
PMID:10860543 PMID:25440059 |
|
NCBI chr 7:100,142,544...100,148,836
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Vav2 |
vav 2 oncogene |
multiple interactions increases abundance |
EXP |
2-acetylphenothiazine inhibits the reaction [VAV2 protein results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [VAV2 protein results in increased abundance of Superoxides] |
CTD |
PMID:23940720 |
|
NCBI chr 2:27,152,116...27,317,620
Ensembl chr 2:27,152,116...27,317,045
|
|
G |
Vdr |
vitamin D (1,25-dihydroxyvitamin D3) receptor |
decreases abundance |
EXP |
VDR protein results in decreased abundance of Superoxides |
CTD |
PMID:25201890 |
|
NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions increases chemical synthesis |
ISO |
[[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein; CAT protein inhibits the reaction [[[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein]; taxifolin inhibits the reaction [XDH protein results in increased chemical synthesis of Superoxides] |
CTD |
PMID:19268487 PMID:19555678 |
|
NCBI chr17:74,190,890...74,257,369
Ensembl chr17:74,190,890...74,257,191
|
|